



## Clinical trial results:

**A Phase II, open-label, randomised controlled study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals' candidate tuberculosis (TB) vaccine (M72/AS01E) when administered intramuscularly according to different immunisation schedules to healthy infants, living in a TB-endemic region**

### Summary

EudraCT number	2012-004380-44
Trial protocol	Outside EU/EEA
Global end of trial date	16 March 2012

### Results information

Result version number	v4 (current)
This version publication date	19 April 2023
First version publication date	18 July 2015
Version creation reason	<ul style="list-style-type: none"><li>• Correction of full data set</li></ul> Correction of full data set and alignment between registries.

### Trial information

#### Trial identification

Sponsor protocol code	112899
-----------------------	--------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01098474
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	GlaxoSmithKline Biologicals,
Sponsor organisation address	Rue de l'Institut 89, Rixensart, Belgium, B-1330
Public contact	Clinical Trials Call Center, GlaxoSmithKline Biologicals, 44 2089904466, GSKClinicalSupportHD@gsk.com
Scientific contact	Clinical Trials Call Center, GlaxoSmithKline Biologicals, 44 2089904466, GSKClinicalSupportHD@gsk.com

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	17 July 2012
Is this the analysis of the primary completion data?	Yes
Primary completion date	30 April 2011
Global end of trial reached?	Yes
Global end of trial date	16 March 2012
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To evaluate the safety of 1 or 2 doses of the TB candidate vaccine when given to healthy infants concomitantly with the EPI regimen containing the DTPw-HBV/Hib, 7Pn and OPV vaccines.  
To evaluate the safety of 1 or 2 doses of the TB candidate vaccine when given to healthy infants after receiving the EPI vaccines containing the DTPw-HBV/Hib, 7Pn and OPV vaccines.

Protection of trial subjects:

All subjects were supervised after vaccination/product administration with appropriate medical treatment readily available. Vaccines were administered by qualified and trained personnel. Vaccines were administered only to eligible subjects that had no contraindications to any components of the vaccines.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	07 July 2010
Long term follow-up planned	Yes
Long term follow-up rationale	Safety
Long term follow-up duration	12 Months
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Gambia: 301
Worldwide total number of subjects	301
EEA total number of subjects	0

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	301
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	0

From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

One enrolled subject was not administered any vaccine and hence was not considered as having started the study.

### Pre-assignment period milestones

Number of subjects started	301
Number of subjects completed	300

### Pre-assignment subject non-completion reasons

Reason: Number of subjects	No vaccination received: 1
----------------------------	----------------------------

### Period 1

Period 1 title	Active Phase
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	SB692342 2 dose Group

Arm description:

Subjects received two doses of SB692342 vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, 1 month apart, on a 0, 1 month schedule after having completed their primary EPI regimen.

Arm type	Experimental
Investigational medicinal product name	GSK Biologicals' candidate tuberculosis vaccine (692342)
Investigational medicinal product code	
Other name	SB692342
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Two doses of 0,5 mL vaccine were administered intramuscularly in the anterolateral region of the right thigh, on a 0, 1 month schedule after having completed their primary EPI regimen.

<b>Arm title</b>	SB692342 1 dose Group
------------------	-----------------------

Arm description:

Subjects received one dose of SB692342 vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, at Month 0, after having completed their primary EPI regimen.

Arm type	Experimental
Investigational medicinal product name	GSK Biologicals' candidate tuberculosis vaccine (692342)
Investigational medicinal product code	
Other name	SB692342
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

**Dosage and administration details:**

One dose of 0,5 mL vaccine was administered intramuscularly in the anterolateral region of the right thigh, at Month 0, after having completed their primary EPI regimen.

<b>Arm title</b>	Control Menjugate Group
------------------	-------------------------

**Arm description:**

Subjects received three doses of the control Menjugate vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, on a 0, 1, 7 months schedule. The first two doses were administered 1 month apart during the primary vaccination phase and the third dose was administered 6 months after the last primary vaccination dose.

Arm type	Active comparator
Investigational medicinal product name	Menjugate
Investigational medicinal product code	
Other name	MenC
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

**Dosage and administration details:**

Three doses of the 0,5 mL control vaccine were administered intramuscularly in the anterolateral region of the right thigh, on a 0, 1, 7 months schedule. The first 2 doses were administered 1 month apart during the primary vaccination phase and the third dose was administered 6 months after the last primary vaccination dose.

<b>Arm title</b>	SB692392 2dose + Tritanrix + Prevnar + Polio Sabin Group
------------------	--

**Arm description:**

Subjects received two doses of SB692342 vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, 1 month apart, concomitantly with the last two doses of the primary EPI regimen containing Tritanrix HepB+Hiberix vaccine, administered intramuscularly in the anterolateral region of the left thigh, Polio Sabin vaccine, administered orally, and Prevnar vaccine, administered intramuscularly in the right arm, on a 0, 1, 2 months schedule. All subjects received a booster dose of the Tritanrix HepB+Hiberix, Polio Sabin and Prevnar vaccines approximately 1 year after their last dose.

Arm type	Experimental
Investigational medicinal product name	GSK Biologicals' candidate tuberculosis vaccine (692342)
Investigational medicinal product code	
Other name	SB692342
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

**Dosage and administration details:**

Two doses of GSK's investigational vaccine 692342 (0,5 mL) were administered, 1 Month apart, intramuscularly in the anterolateral region of the right thigh, concomitantly with the last two doses of the primary EPI regimen containing Tritanrix, HepB+Hiberix, Polio Sabin and Prevnar, on a 1, 2 months schedule.

Investigational medicinal product name	Tritanrix HepB+Hiberix
Investigational medicinal product code	
Other name	DTPw-HBV/Hib
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

**Dosage and administration details:**

The last two doses of the primary EPI regimen containing Tritanrix HepB+Hiberix, received intramuscularly in the anterolateral region of the left thigh, Polio Sabin and Prevnar were administered together with two doses of GSK's investigational vaccine 692342, on a 1, 2 months schedule.

Investigational medicinal product name	Polio Sabin
Investigational medicinal product code	
Other name	OPV

Pharmaceutical forms	Suspension for injection
Routes of administration	Oral use

**Dosage and administration details:**

The last two doses of the primary EPI regimen containing Tritanrix HepB+Hiberix, Polio Sabin received orally and Pevnar were administered together with two doses of GSK's investigational vaccine 692342, on a 1, 2 months schedule.

Investigational medicinal product name	Pevnar
Investigational medicinal product code	
Other name	7Pn
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

**Dosage and administration details:**

The last two doses of the primary EPI regimen containing Tritanrix HepB+Hiberix, Polio Sabin and Pevnar received intramuscularly in the right arm, were administered together with two doses of GSK's investigational vaccine 692342, on a 1, 2 months schedule.

<b>Arm title</b>	SB692392 1 dose +Tritanrix + Pevnar+ Polio Sabin Group
------------------	--

**Arm description:**

Subjects received one dose of SB692342 vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, concomitantly with the last dose of the primary EPI regimen containing Tritanrix HepB+Hiberix vaccine, administered intramuscularly in the anterolateral region of the left thigh, Polio Sabin vaccine, administered orally, and Pevnar vaccine, administered intramuscularly in the right arm, on a 0, 1, 2 months schedule. All subjects received a booster dose of the Tritanrix HepB+Hiberix, Polio Sabin and Pevnar vaccines approximately 1 year after their last dose.

Arm type	Experimental
Investigational medicinal product name	GSK Biologicals' candidate tuberculosis vaccine (692342)
Investigational medicinal product code	
Other name	SB692342
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

**Dosage and administration details:**

One dose of GSK's investigational vaccine 692342 (0,5 mL) was administered, intramuscularly in the anterolateral region of the right thigh, concomitantly with the last dose of the primary EPI regimen containing Tritanrix, HepB+Hiberix, Polio Sabin and Pevnar, at month 2.

Investigational medicinal product name	Tritanrix HepB+Hiberix
Investigational medicinal product code	
Other name	DTPw-HBV/Hib
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

**Dosage and administration details:**

The last dose of the primary EPI regimen containing Tritanrix HepB+Hiberix, received intramuscularly in the anterolateral region of the left thigh, Polio Sabin and Pevnar was administered together with one dose of GSK's investigational vaccine 692342, at month 2.

Investigational medicinal product name	Polio Sabin
Investigational medicinal product code	
Other name	OPV
Pharmaceutical forms	Suspension for injection
Routes of administration	Oral use

**Dosage and administration details:**

The last dose of the primary EPI regimen containing Tritanrix HepB+Hiberix, Polio Sabin received orally and Pevnar was administered together with one dose of GSK's investigational vaccine 692342, at month 2.

Investigational medicinal product name	Pevnar
Investigational medicinal product code	
Other name	7Pn
Pharmaceutical forms	Injection

Routes of administration	Intramuscular use
--------------------------	-------------------

Dosage and administration details:

The last dose of the primary EPI regimen containing Tritanrix HepB+Hiberix, Polio Sabin and Pevnar received intramuscularly in the right arm, was administered together with one dose of GSK's investigational vaccine 692342, at month 2.

<b>Arm title</b>	Control Tritanrix + Pevnar + Polio Sabin Group
------------------	--

Arm description:

Subjects received three doses of the primary EPI regimen containing Tritanrix HepB+Hiberix vaccine, administered in the anterolateral region of the left thigh, Polio Sabin vaccine, administered orally, and Pevnar vaccine administered intramuscularly in the right arm, on a 0, 1, 2 months schedule. All subjects received a booster dose of the Tritanrix HepB+Hiberix, Polio Sabin and Pevnar vaccines approximately 1 year after their last dose.

Arm type	Active comparator
Investigational medicinal product name	Tritanrix HepB+Hiberix
Investigational medicinal product code	
Other name	DTPw-HBV/Hib
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Three doses of the primary EPI regimen containing Tritanrix HepB+Hiberix, Polio Sabin and Pevnar were administered on a 0, 1, 2 Months schedule.

Investigational medicinal product name	Pevnar
Investigational medicinal product code	
Other name	7Pn
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Three doses of the primary EPI regimen containing Tritanrix HepB+Hiberix, Polio Sabin and Pevnar were administered on a 0, 1, 2 Months schedule.

Investigational medicinal product name	Polio Sabin
Investigational medicinal product code	
Other name	OPV
Pharmaceutical forms	Suspension for injection
Routes of administration	Oral use

Dosage and administration details:

Three doses of the primary EPI regimen containing Tritanrix HepB+Hiberix, Polio Sabin and Pevnar were administered on a 0, 1, 2 Months schedule.

<b>Number of subjects in period 1<sup>[1]</sup></b>	SB692342 2 dose Group	SB692342 1 dose Group	Control Menjugate Group
Started	50	50	50
Completed	48	49	45
Not completed	2	1	5
Consent withdrawn by subject	1	1	2
Unspecified	-	-	3
Lost to follow-up	1	-	-

<b>Number of subjects in period 1<sup>[1]</sup></b>	<b>SB692392 2dose + Tritanrix + Pevnar + Polio Sabin Group</b>	<b>SB692392 1 dose +Tritanrix + Pevnar+ Polio Sabin Group</b>	<b>Control Tritanrix + Pevnar + Polio Sabin Group</b>
Started	49	52	49
Completed	49	52	49
Not completed	0	0	0
Consent withdrawn by subject	-	-	-
Unspecified	-	-	-
Lost to follow-up	-	-	-

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: One enrolled subject was not administered any vaccine and hence was not considered as having started the study.

## Period 2

Period 2 title	Follow-up Phase
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Not blinded

## Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	<b>SB692392 2 dose + Tritanrix + Pevnar + Polio Sabin Group</b>

Arm description:

Subjects received two doses of SB692342 vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, 1 month apart, concomitantly with the last two doses of the primary EPI regimen containing Tritanrix HepB+Hiberix vaccine, administered intramuscularly in the anterolateral region of the left thigh, Polio Sabin vaccine, administered orally, and Pevnar vaccine, administered intramuscularly in the right arm, on a 0, 1, 2 months schedule.

All subjects received a booster dose of the Tritanrix HepB+Hiberix, Polio Sabin and Pevnar vaccines approximately 1 year after their last dose.

Arm type	Experimental
Investigational medicinal product name	GSK Biologicals' candidate tuberculosis vaccine (692342)
Investigational medicinal product code	
Other name	SB692342
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Two doses of GSK's investigational vaccine 692342 (0,5 mL) were administered, 1 Month apart, intramuscularly in the anterolateral region of the right thigh, concomitantly with the last two doses of the primary EPI regimen containing Tritanrix, HepB+Hiberix, Polio Sabin and Pevnar, at month 1 and 2 during the active phase.

Investigational medicinal product name	Tritanrix HepB+Hiberix
Investigational medicinal product code	
Other name	DTPw-HBV/Hib
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

The last two doses of the primary EPI regimen containing Tritanrix HepB+Hiberix, received intramuscularly in the anterolateral region of the left thigh, Polio Sabin and Pevnar were administered together with two doses of GSK's investigational vaccine 692342.

All subjects received a booster dose of the Tritanrix HepB+Hiberix, Polio Sabin and Pevnar vaccines approximately 1 year after their last dose.



Investigational medicinal product name	Polio Sabin
Investigational medicinal product code	
Other name	OPV
Pharmaceutical forms	Suspension for injection
Routes of administration	Oral use

**Dosage and administration details:**

The last two doses of the primary EPI regimen containing Tritanrix HepB+Hiberix, Polio Sabin received orally and Prevnar were administered together with two doses of GSK's investigational vaccine 692342. All subjects received a booster dose of the Tritanrix HepB+Hiberix, Polio Sabin and Prevnar vaccines approximately 1 year after their last dose.

Investigational medicinal product name	Prevnar
Investigational medicinal product code	
Other name	7Pn
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

**Dosage and administration details:**

The last two doses of the primary EPI regimen containing Tritanrix HepB+Hiberix, Polio Sabin and Prevnar received intramuscularly in the right arm, were administered together with two doses of GSK's investigational vaccine 692342.

All subjects received a booster dose of the Tritanrix HepB+Hiberix, Polio Sabin and Prevnar vaccines approximately 1 year after their last dose.

<b>Arm title</b>	SB692392 1 dose + Tritanrix + Prevnar + Polio Sabin Group
------------------	---

**Arm description:**

Subjects received one dose of SB692342 vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, concomitantly with the last dose of the primary EPI regimen containing Tritanrix HepB+Hiberix vaccine, administered intramuscularly in the anterolateral region of the left thigh, Polio Sabin vaccine, administered orally, and Prevnar vaccine, administered intramuscularly in the right arm, on a 0, 1, 2 months schedule. All subjects received a booster dose of the Tritanrix HepB+Hiberix, Polio Sabin and Prevnar vaccines approximately 1 year after their last dose.

Arm type	Experimental
Investigational medicinal product name	GSK Biologicals' candidate tuberculosis vaccine (692342)
Investigational medicinal product code	
Other name	SB692342
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

**Dosage and administration details:**

One dose of GSK's investigational vaccine 692342 (0,5 mL) was were administered, 1 Month apart, intramuscularly in the anterolateral region of the right thigh, concomitantly with the last dose of the primary EPI regimen containing Tritanrix™ HepB+Hiberix™, Polio Sabin™ administered orally and Prevnar® administered intramuscularly in the right arm.

Investigational medicinal product name	Tritanrix HepB+Hiberix
Investigational medicinal product code	
Other name	DTPw-HBV/Hib
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

**Dosage and administration details:**

The last dose of the primary EPI regimen containing Tritanrix HepB+Hiberix, received intramuscularly in the anterolateral region of the left thigh, Polio Sabin and Prevnar were administered together with one dose of GSK's investigational vaccine 692342.

Investigational medicinal product name	Polio Sabin
Investigational medicinal product code	
Other name	OPV
Pharmaceutical forms	Suspension for injection
Routes of administration	Oral use

Dosage and administration details:	
The last dose of the primary EPI regimen containing Tritanrix HepB+Hiberix , Polio Sabin received orally and Pevnar were administered together with one dose of GSK's investigational vaccine 692342.	
Investigational medicinal product name	Pevnar
Investigational medicinal product code	
Other name	7Pn
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

The last dose of the primary EPI regimen containing Tritanrix HepB+Hiberix, Polio Sabin and Pevnar received intramuscularly in the right arm, were administered together with one dose of GSK's investigational vaccine 692342.

<b>Arm title</b>	Control Tritanrix + Pevnar + Polio Sabin Group
------------------	--

Arm description:

Subjects received three doses of the primary EPI regimen containing Tritanrix HepB+Hiberix vaccine, administered in the anterolateral region of the left thigh, Polio Sabin vaccine, administered orally, and Pevnar vaccine administered intramuscularly in the right arm, on a 0, 1, 2 months schedule. All subjects received a booster dose of the Tritanrix HepB+Hiberix, Polio Sabin and Pevnar vaccines approximately 1 year after their last dose.

Arm type	Active comparator
Investigational medicinal product name	Tritanrix HepB+Hiberix
Investigational medicinal product code	
Other name	DTPw-HBV/Hib
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Three doses of the primary EPI regimen containing Tritanrix HepB+Hiberix, Polio Sabin and Pevnar were administered on a 0, 1, 2 Months schedule.

Investigational medicinal product name	Pevnar
Investigational medicinal product code	
Other name	7Pn
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Three doses of the primary EPI regimen containing Tritanrix HepB+Hiberix, Polio Sabin and Pevnar were administered on a 0, 1, 2 Months schedule.

Investigational medicinal product name	Polio Sabin
Investigational medicinal product code	
Other name	OPV
Pharmaceutical forms	Suspension for injection
Routes of administration	Oral use

Dosage and administration details:

Three doses of the primary EPI regimen containing Tritanrix HepB+Hiberix, Polio Sabin and Pevnar were administered on a 0, 1, 2 Months schedule.

<b>Arm title</b>	SB692342 2 dose Group
------------------	-----------------------

Arm description:

Subjects received two doses of SB692342 vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, 1 month apart, on a 0, 1 month schedule after having completed their primary EPI regimen.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	GSK Biologicals' candidate tuberculosis vaccine (692342)
Investigational medicinal product code	
Other name	SB692342
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

**Dosage and administration details:**

Two doses of 0,5 mL vaccine were administered intramuscularly in the anterolateral region of the right thigh, on a 0, 1 month schedule after having completed their primary EPI regimen.

<b>Arm title</b>	SB692342 1 dose Group
------------------	-----------------------

**Arm description:**

Subjects received one dose of SB692342 vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, at Month 0, after having completed their primary EPI regimen.

Arm type	Experimental
Investigational medicinal product name	GSK Biologicals' candidate tuberculosis vaccine (692342)
Investigational medicinal product code	
Other name	SB692342
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

**Dosage and administration details:**

One dose of 0,5 mL vaccine was administered intramuscularly in the anterolateral region of the right thigh, at Month 0, after having completed their primary EPI regimen.

<b>Arm title</b>	Control Menjugate Group
------------------	-------------------------

**Arm description:**

Subjects received three doses of the control Menjugate vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, on a 0, 1, 7 months schedule. The first two doses were administered 1 month apart during the primary vaccination phase and the third dose was administered 6 months after the last primary vaccination dose.

Arm type	Active comparator
Investigational medicinal product name	Menjugate
Investigational medicinal product code	
Other name	MenC
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

**Dosage and administration details:**

Three doses of 0,5 mL control vaccine were administered intramuscularly in the anterolateral region of the right thigh, on a 0, 1, 7 months schedule. The first 2 doses were administered 1 month apart during the primary vaccination phase and the third dose was administered 6 months after the last primary vaccination dose.

<b>Number of subjects in period 2</b>	SB692392 2 dose + Tritanrix + Prevnar + Polio Sabin Group	SB692392 1 dose + Tritanrix + Prevnar + Polio Sabin Group	Control Tritanrix + Prevnar + Polio Sabin Group
Started	49	52	49
Completed	47	50	44
Not completed	2	2	5
Consent withdrawn by subject	2	-	1
Travelled out of study area	-	1	-
Unspecified	-	-	4

Lost to follow-up	-	1	-
-------------------	---	---	---

  

<b>Number of subjects in period 2</b>	SB692342 2 dose Group	SB692342 1 dose Group	Control Menjugate Group
Started	48	49	45
Completed	48	49	45
Not completed	0	0	0
Consent withdrawn by subject	-	-	-
Travelled out of study area	-	-	-
Unspecified	-	-	-
Lost to follow-up	-	-	-

## Baseline characteristics

### Reporting groups

Reporting group title	SB692342 2 dose Group
-----------------------	-----------------------

Reporting group description:

Subjects received two doses of SB692342 vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, 1 month apart, on a 0, 1 month schedule after having completed their primary EPI regimen.

Reporting group title	SB692342 1 dose Group
-----------------------	-----------------------

Reporting group description:

Subjects received one dose of SB692342 vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, at Month 0, after having completed their primary EPI regimen.

Reporting group title	Control Menjugate Group
-----------------------	-------------------------

Reporting group description:

Subjects received three doses of the control Menjugate vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, on a 0, 1, 7 months schedule. The first two doses were administered 1 month apart during the primary vaccination phase and the third dose was administered 6 months after the last primary vaccination dose.

Reporting group title	SB692392 2dose + Tritanrix + Pevnar + Polio Sabin Group
-----------------------	---

Reporting group description:

Subjects received two doses of SB692342 vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, 1 month apart, concomitantly with the last two doses of the primary EPI regimen containing Tritanrix HepB+Hiberix vaccine, administered intramuscularly in the anterolateral region of the left thigh, Polio Sabin vaccine, administered orally, and Pevnar vaccine, administered intramuscularly in the right arm, on a 0, 1, 2 months schedule.

All subjects received a booster dose of the Tritanrix HepB+Hiberix, Polio Sabin and Pevnar vaccines approximately 1 year after their last dose.

Reporting group title	SB692392 1 dose +Tritanrix + Pevnar+ Polio Sabin Group
-----------------------	--

Reporting group description:

Subjects received one dose of SB692342 vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, concomitantly with the last dose of the primary EPI regimen containing Tritanrix HepB+Hiberix vaccine, administered intramuscularly in the anterolateral region of the left thigh, Polio Sabin vaccine, administered orally, and Pevnar vaccine, administered intramuscularly in the right arm, on a 0, 1, 2 months schedule. All subjects received a booster dose of the Tritanrix HepB+Hiberix, Polio Sabin and Pevnar vaccines approximately 1 year after their last dose.

Reporting group title	Control Tritanrix + Pevnar + Polio Sabin Group
-----------------------	--

Reporting group description:

Subjects received three doses of the primary EPI regimen containing Tritanrix HepB+Hiberix vaccine, administered in the anterolateral region of the left thigh, Polio Sabin vaccine, administered orally, and Pevnar vaccine administered intramuscularly in the right arm, on a 0, 1, 2 months schedule. All subjects received a booster dose of the Tritanrix HepB+Hiberix, Polio Sabin and Pevnar vaccines approximately 1 year after their last dose.

Reporting group values	SB692342 2 dose Group	SB692342 1 dose Group	Control Menjugate Group
Number of subjects	50	50	50
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0

Infants and toddlers (28 days-23 months)	50	50	50
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	0	0	0
From 65-84 years	0	0	0
85 years and over	0	0	0
Age continuous Units: months arithmetic mean standard deviation	5.8 ± 0.68	5.7 ± 0.61	5.7 ± 0.65
Gender categorical Units: Subjects			
Female	34	20	23
Male	16	30	27

<b>Reporting group values</b>	SB692392 2dose + Tritanrix + Prevnar + Polio Sabin Group	SB692392 1 dose +Tritanrix + Prevnar+ Polio Sabin Group	Control Tritanrix + Prevnar + Polio Sabin Group
Number of subjects	49	52	49
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	49	52	49
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	0	0	0
From 65-84 years	0	0	0
85 years and over	0	0	0
Age continuous Units: months arithmetic mean standard deviation	2.1 ± 0.28	2 ± 0.19	2.1 ± 0.31
Gender categorical Units: Subjects			
Female	25	16	23
Male	24	36	26

<b>Reporting group values</b>	Total		
Number of subjects	300		
Age categorical Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	300		
Children (2-11 years)	0		

Adolescents (12-17 years)	0		
Adults (18-64 years)	0		
From 65-84 years	0		
85 years and over	0		
Age continuous			
Units: months			
arithmetic mean			
standard deviation	-		
Gender categorical			
Units: Subjects			
Female	141		
Male	159		

## End points

### End points reporting groups

Reporting group title	SB692342 2 dose Group
Reporting group description: Subjects received two doses of SB692342 vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, 1 month apart, on a 0, 1 month schedule after having completed their primary EPI regimen.	
Reporting group title	SB692342 1 dose Group
Reporting group description: Subjects received one dose of SB692342 vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, at Month 0, after having completed their primary EPI regimen.	
Reporting group title	Control Menjugate Group
Reporting group description: Subjects received three doses of the control Menjugate vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, on a 0, 1, 7 months schedule. The first two doses were administered 1 month apart during the primary vaccination phase and the third dose was administered 6 months after the last primary vaccination dose.	
Reporting group title	SB692392 2dose + Tritanrix + Pevnar + Polio Sabin Group
Reporting group description: Subjects received two doses of SB692342 vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, 1 month apart, concomitantly with the last two doses of the primary EPI regimen containing Tritanrix HepB+Hiberix vaccine, administered intramuscularly in the anterolateral region of the left thigh, Polio Sabin vaccine, administered orally, and Pevnar vaccine, administered intramuscularly in the right arm, on a 0, 1, 2 months schedule. All subjects received a booster dose of the Tritanrix HepB+Hiberix, Polio Sabin and Pevnar vaccines approximately 1 year after their last dose.	
Reporting group title	SB692392 1 dose +Tritanrix + Pevnar+ Polio Sabin Group
Reporting group description: Subjects received one dose of SB692342 vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, concomitantly with the last dose of the primary EPI regimen containing Tritanrix HepB+Hiberix vaccine, administered intramuscularly in the anterolateral region of the left thigh, Polio Sabin vaccine, administered orally, and Pevnar vaccine, administered intramuscularly in the right arm, on a 0, 1, 2 months schedule. All subjects received a booster dose of the Tritanrix HepB+Hiberix, Polio Sabin and Pevnar vaccines approximately 1 year after their last dose.	
Reporting group title	Control Tritanrix + Pevnar + Polio Sabin Group
Reporting group description: Subjects received three doses of the primary EPI regimen containing Tritanrix HepB+Hiberix vaccine, administered in the anterolateral region of the left thigh, Polio Sabin vaccine, administered orally, and Pevnar vaccine administered intramuscularly in the right arm, on a 0, 1, 2 months schedule. All subjects received a booster dose of the Tritanrix HepB+Hiberix, Polio Sabin and Pevnar vaccines approximately 1 year after their last dose.	
Reporting group title	SB692392 2 dose + Tritanrix + Pevnar + Polio Sabin Group
Reporting group description: Subjects received two doses of SB692342 vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, 1 month apart, concomitantly with the last two doses of the primary EPI regimen containing Tritanrix HepB+Hiberix vaccine, administered intramuscularly in the anterolateral region of the left thigh, Polio Sabin vaccine, administered orally, and Pevnar vaccine, administered intramuscularly in the right arm, on a 0, 1, 2 months schedule. All subjects received a booster dose of the Tritanrix HepB+Hiberix, Polio Sabin and Pevnar vaccines approximately 1 year after their last dose.	
Reporting group title	SB692392 1 dose + Tritanrix + Pevnar + Polio Sabin Group
Reporting group description: Subjects received one dose of SB692342 vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, concomitantly with the last dose of the primary EPI regimen	



containing Tritanrix HepB+Hiberix vaccine, administered intramuscularly in the anterolateral region of the left thigh, Polio Sabin vaccine, administered orally, and Prevnar vaccine, administered intramuscularly in the right arm, on a 0, 1, 2 months schedule. All subjects received a booster dose of the Tritanrix HepB+Hiberix, Polio Sabin and Prevnar vaccines approximately 1 year after their last dose.

Reporting group title	Control Tritanrix + Prevnar + Polio Sabin Group
-----------------------	---

Reporting group description:

Subjects received three doses of the primary EPI regimen containing Tritanrix HepB+Hiberix vaccine, administered in the anterolateral region of the left thigh, Polio Sabin vaccine, administered orally, and Prevnar vaccine administered intramuscularly in the right arm, on a 0, 1, 2 months schedule. All subjects received a booster dose of the Tritanrix HepB+Hiberix, Polio Sabin and Prevnar vaccines approximately 1 year after their last dose.

Reporting group title	SB692342 2 dose Group
-----------------------	-----------------------

Reporting group description:

Subjects received two doses of SB692342 vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, 1 month apart, on a 0, 1 month schedule after having completed their primary EPI regimen.

Reporting group title	SB692342 1 dose Group
-----------------------	-----------------------

Reporting group description:

Subjects received one dose of SB692342 vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, at Month 0, after having completed their primary EPI regimen.

Reporting group title	Control Menjugate Group
-----------------------	-------------------------

Reporting group description:

Subjects received three doses of the control Menjugate vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, on a 0, 1, 7 months schedule. The first two doses were administered 1 month apart during the primary vaccination phase and the third dose was administered 6 months after the last primary vaccination dose.

### Primary: Number of subjects with grade 3 solicited local symptoms after dose 1, dose 2 and across doses

End point title	Number of subjects with grade 3 solicited local symptoms after dose 1, dose 2 and across doses <sup>[1][2]</sup>
-----------------	--

End point description:

Solicited local symptoms assessed were pain, redness and swelling. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 20 millimeters (mm) of injection site.

End point type	Primary
----------------	---------

End point timeframe:

From Day 0 to Day 6

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting values for the SB692342 2 dose Group, the SB692342 1 dose Group and the Control Menjugate Group from the baseline period.

End point values	SB692342 2 dose Group	SB692342 1 dose Group	Control Menjugate Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	50	50	50	
Units: Subjects				
Grade 3 Pain, D1 (N=50,50,50)	0	0	0	
Grade 3 Swelling, D1 (N=50,50,50)	0	0	0	
Grade 3 Pain, D2 (N=49,0,48)	0	0	0	
Grade 3 Swelling, D2 (N=49,0,48)	0	0	0	
Grade 3 Pain, Across (N=50,50,50)	0	0	0	
Grade 3 Swelling, Across (N=50,50,50)	0	0	0	

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of subjects with grade 3 solicited local symptoms after dose 2, dose 3 and across doses

End point title	Number of subjects with grade 3 solicited local symptoms after dose 2, dose 3 and across doses <sup>[3]</sup>
-----------------	---

End point description:

Solicited local symptoms were only collected after Dose 2 of EPI vaccination. Solicited local symptoms assessed were pain, redness and swelling. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 20 millimeters (mm) of injection site.

End point type	Primary
----------------	---------

End point timeframe:

From Day 0 to Day 6

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	SB692392 2 dose + Tritanrix + Prevnar + Polio Sabin Group	SB692392 1 dose + Tritanrix + Prevnar + Polio Sabin Group	Control Tritanrix + Prevnar + Polio Sabin Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	47	52	48	
Units: Subjects				
Grade 3 Pain, D2 (N=47,0,47)	0	0	0	
Grade 3 Swelling, D2 (N=47,0,47)	2	0	2	
Grade 3 Pain, D3 (N=47,52,48)	2	0	0	
Grade 3 Swelling, D3 (N=47,52,48)	3	6	3	
Grade 3 Pain, Across (N=47,52,48)	2	0	0	
Grade 3 Swelling, Across (N=47,52,48)	3	6	5	

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of subjects with grade 3 solicited general symptoms after dose 1, dose 2 and across doses

End point title	Number of subjects with grade 3 solicited general symptoms after dose 1, dose 2 and across doses <sup>[4]</sup> <sup>[5]</sup>
-----------------	--

End point description:

Solicited general symptoms assessed were drowsiness, fever [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)], irritability/fussiness and loss of appetite. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever > 39.0 °C.

End point type	Primary
----------------	---------

End point timeframe:

From Day 0 to Day 6

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting values for the SB692342 2 dose Group, the SB692342 1 dose Group and the Control Menjugate Group from the baseline period.

End point values	SB692342 2 dose Group	SB692342 1 dose Group	Control Menjugate Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	50	50	50	
Units: Subjects				
Grade 3 Drowsiness, D1 (N=50,50,50)	0	0	0	
Grade 3 Irritability, D1 (N=50,50,50)	0	0	0	
Grade 3 Loss of appetite, D1 (N=50,50,50)	0	0	0	
Grade 3 Temperature /Axillary, D1 (N=50,50,50)	0	0	0	
Grade 3 Drowsiness, D2 (N=49,0 ,48)	0	0	0	
Grade 3 Irritability, D2 (N=49,0,48)	0	0	0	
Grade 3 Loss of appetite, D2 (N=49,0,48)	0	0	0	
Grade 3 Temperature/Axillary, D2 (N=49,0,48)	0	0	1	
Grade 3 Drowsiness, Across (N=50,50,50)	0	0	0	
Grade 3 Irritability, Across (N=50,50,50)	0	0	0	
Grade 3 Loss of appetite, Across (N=50,50,50)	0	0	0	
Grade 3 Fever/Axillary, Across (N=50,50,50)	0	0	1	

## Statistical analyses

**Primary: Number of subjects with grade 3 solicited general symptoms after dose 2, dose 3 and across doses**

End point title	Number of subjects with grade 3 solicited general symptoms after dose 2, dose 3 and across doses <sup>[6]</sup>
-----------------	---

## End point description:

Solicited general symptoms were only collected after Dose 2 of EPI vaccination. Solicited general symptoms assessed were drowsiness, fever [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)], irritability/fussiness and loss of appetite. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever > 39.0 °C.

End point type	Primary
----------------	---------

## End point timeframe:

From Day 0 to Day 6

## Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	SB692392 2 dose + Tritanrix + Prevnar + Polio Sabin Group	SB692392 1 dose + Tritanrix + Prevnar + Polio Sabin Group	Control Tritanrix + Prevnar + Polio Sabin Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	47	52	48	
Units: Subjects				
Grade 3 Drowsiness, D2 (N=47,0 ,47)	0	0	0	
Grade 3 Irritability, D2 (N=47,0,47)	0	0	0	
Grade 3 Loss of appetite, D2 (N=47,0,47)	0	0	0	
Grade 3 Temperature/Axillary, D2 (N=47,0,47)	0	0	0	
Grade 3 Drowsiness, D3 (N=47,52,48)	0	0	0	
Grade 3 Irritability, D3 (N=47,52,48)	2	0	0	
Grade 3 Loss of appetite, D3 (N=47,52,48)	0	0	0	
Grade 3 Temperature/Axillary, D3 (N=47,52,48)	0	0	0	
Grade 3 Drowsiness, Across (N=47,52,48)	0	0	0	
Grade 3 Irritability, Across (N=47,52,48)	2	0	0	
Grade 3 Loss of appetite, Across (N=47,52,48)	0	0	0	
Grade 3 Fever/Axillary, Across (N=47,52,48)	0	0	0	

**Statistical analyses**

No statistical analyses for this end point

**Primary: Number of subjects with grade 3 unsolicited adverse events (AEs)**

End point title	Number of subjects with grade 3 unsolicited adverse events (AEs) <sup>[7][8]</sup>
-----------------	--

End point description:

An unsolicited adverse event is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

End point type	Primary
----------------	---------

End point timeframe:

From Day 0 to Day 29

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting values for the SB692342 2 dose Group, the SB692342 1 dose Group and the Control Menjugate Group from the baseline period.

End point values	SB692342 2 dose Group	SB692392 2 dose + Tritanrix + Pevnar + Polio Sabin Group	SB692342 1 dose Group	SB692392 1 dose + Tritanrix + Pevnar + Polio Sabin Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	50	47	50	52
Units: Subjects				
Grade 3 AEs	28	25	27	14

End point values	Control Menjugate Group	Control Tritanrix + Pevnar + Polio Sabin Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	50	48		
Units: Subjects				
Grade 3 AEs	26	22		

**Statistical analyses**

No statistical analyses for this end point

**Primary: Number of subjects with serious adverse events (SAEs)**

End point title	Number of subjects with serious adverse events (SAEs) <sup>[9][10]</sup>
-----------------	--

End point description:

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

End point type	Primary
----------------	---------

End point timeframe:

From Month 0 to Month 17

Notes:

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting values for the SB692342 2 dose Group, the SB692342 1 dose Group and the Control Menjugate Group from the baseline period.

End point values	SB692342 2 dose Group	SB692392 2 dose + Tritanrix + Pevnar + Polio Sabin Group	SB692342 1 dose Group	SB692392 1 dose + Tritanrix + Pevnar + Polio Sabin Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	50	49	50	52
Units: Subjects				
Any SAEs	0	1	0	0

End point values	Control Menjugate Group	Control Tritanrix + Pevnar + Polio Sabin Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	50	49		
Units: Subjects				
Any SAEs	1	0		

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of subjects with grade 3 haematological and biochemical levels

End point title	Number of subjects with grade 3 haematological and biochemical levels <sup>[11][12]</sup>
-----------------	---

End point description:

Haematological/Biochemical parameters assessed were: Haemoglobin (Haem), White Blood Cells (WBC), Platelets (PLA), Alanine Aminotransferase (ALA) and Creatinine (CREA). Grade 3 = Haem.: lesser than (<) 5.0 grams per deciliter (g/dL); WBC.: 1.0 to 1.4 x 10<sup>3</sup>/micro liter (μL); PLA.: < 25x10<sup>3</sup>/μL; ALA.: 5.1 to 10.0 x upper limit of normal (ULN) and CREA: 3.1 to 6.0 x ULN.

End point type	Primary
----------------	---------

End point timeframe:

At Day 0

Notes:

[11] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting values for the SB692342 2 dose Group, the SB692342 1 dose Group and the Control Menjugate Group from the baseline period.

End point values	SB692342 2 dose Group	SB692392 2 dose + Tritanrix + Pevnar + Polio Sabin Group	SB692342 1 dose Group	SB692392 1 dose + Tritanrix + Pevnar + Polio Sabin Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	50	49	50	52
Units: Subjects				
Haem, PRE, Grade 3	0	0	0	0
WBC, PRE, Grade 3	0	0	0	0
PLA, PRE, Grade 3	0	0	0	0
ALA, PRE, Grade 3	0	0	0	0
CREA PRE, Grade 3	0	0	0	0

End point values	Control Menjugate Group	Control Tritanrix + Pevnar + Polio Sabin Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	50	49		
Units: Subjects				
Haem, PRE, Grade 3	0	0		
WBC, PRE, Grade 3	0	0		
PLA, PRE, Grade 3	0	0		
ALA, PRE, Grade 3	0	0		
CREA PRE, Grade 3	0	0		

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of subjects with grade 3 haematological and biochemical levels

End point title	Number of subjects with grade 3 haematological and biochemical levels <sup>[13][14]</sup>
End point description: Haematological/Biochemical parameters assessed were: Haemoglobin (Haem), White Blood Cells (WBC), Platelets (PLA), Alanine Aminotransferase (ALA) and Creatinine (CREA). Grade 3 = Haem.: < 5.0 g/dL; WBC.: 1.0 to 1.4 x 10 <sup>3</sup> /μL; PLA.: < 25x10 <sup>3</sup> /μL; ALA.: 5.1 to 10.0 x ULN and CREA: 3.1 to 6.0 x ULN.	
End point type	Primary

End point timeframe:

Seven days post Dose 1, at Day 7 [PI(D7)]

Notes:

[13] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

[14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting values for the SB692342 2 dose Group, the SB692342 1 dose Group and the Control Menjugate Group from the baseline period.

End point values	SB692342 2 dose Group	SB692342 1 dose Group	Control Menjugate Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	50	50	50	
Units: Subjects				
Haem, PI(D7), Grade 3	0	0	0	
WBC, PI(D7) Grade 3	0	0	0	
PLA, PI(D7), Grade 3	0	0	0	
ALA, PI(D7), Grade 3	0	0	0	
CREA PI(D7), Grade 3	0	0	0	

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of subjects with grade 3 haematological and biochemical levels

End point title	Number of subjects with grade 3 haematological and biochemical levels <sup>[15][16]</sup>
-----------------	---

End point description:

Haematological/Biochemical parameters assessed were: Haemoglobin (Haem), White Blood Cells (WBC), Platelets (PLA), Alanine Aminotransferase (ALA) and Creatinine (CREA). Grade 3 = Haem.: < 5.0 g/dL; WBC.: 1.0 to 1.4 x 10<sup>3</sup>/μL; PLA.: < 25x10<sup>3</sup>/μL; ALA.: 5.1 to 10.0 x ULN and CREA: 3.1 to 6.0 x ULN.

End point type	Primary
----------------	---------

End point timeframe:

Seven days post Dose 2, at Day 37 [PII(D37)]

Notes:

[15] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

[16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting values for the SB692342 2 dose Group and the Control Menjugate Group from the baseline period.



End point values	SB692342 2 dose Group	SB692392 2 dose + Tritanrix + Pevnar + Polio Sabin Group	SB692392 1 dose + Tritanrix + Pevnar + Polio Sabin Group	Control Menjugate Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	50	49	52	50
Units: Subjects				
Haem, PII(D37), Grade 3	0	0	0	0
WBC, PII(D37) Grade 3	0	0	0	0
PLA, PII(D37), Grade 3	0	0	0	0
ALA, PII(D37), Grade 3	0	0	0	0
CREA PII(D37), Grade 3	0	0	0	0

End point values	Control Tritanrix + Pevnar + Polio Sabin Group			
Subject group type	Reporting group			
Number of subjects analysed	49			
Units: Subjects				
Haem, PII(D37), Grade 3	0			
WBC, PII(D37) Grade 3	0			
PLA, PII(D37), Grade 3	0			
ALA, PII(D37), Grade 3	0			
CREA PII(D37), Grade 3	0			

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of subjects with grade 3 haematological and biochemical levels

End point title	Number of subjects with grade 3 haematological and biochemical levels <sup>[17]</sup>
-----------------	---

End point description:

Haematological/Biochemical parameters assessed were: Haemoglobin (Haem), White Blood Cells (WBC), Platelets (PLA), Alanine Aminotransferase (ALA) and Creatinine (CREA). Grade 3 = Haem.: < 5.0 g/dL; WBC.: 1.0 to 1.4 x 10<sup>3</sup>/μL; PLA.: < 25x10<sup>3</sup>/μL; ALA.: 5.1 to 10.0 x ULN and CREA: 3.1 to 6.0 x ULN.

End point type	Primary
----------------	---------

End point timeframe:

Seven days post Dose 3, at Day 67 [PIII(D67)]

Notes:

[17] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	SB692392 2 dose + Tritanrix + Prevnar + Polio Sabin Group	SB692392 1 dose + Tritanrix + Prevnar + Polio Sabin Group	Control Tritanrix + Prevnar + Polio Sabin Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	49	52	49	
Units: Subjects				
Haem, PIII(D67), Grade 3	0	0	0	
WBC, PIII(D67) Grade 3	0	0	0	
PLA, PIII(D67), Grade 3	0	0	0	
ALA, PIII(D67), Grade 3	0	0	0	
CREA PIII(D67), Grade 3	0	0	0	

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of subjects with grade 3 haematological and biochemical levels

End point title	Number of subjects with grade 3 haematological and biochemical levels <sup>[18]</sup> <sup>[19]</sup>
-----------------	---

End point description:

Haematological/Biochemical parameters assessed were: Haemoglobin (Haem), White Blood Cells (WBC), Platelets (PLA), Alanine Aminotransferase (ALA) and Creatinine (CREA). Grade 3 = Haem.: < 5.0 g/dL; WBC.: 1.0 to 1.4 x 10<sup>3</sup>/μL; PLA.: < 25x10<sup>3</sup>/μL; ALA.: 5.1 to 10.0 x ULN and CREA: 3.1 to 6.0 x ULN.

End point type	Primary
----------------	---------

End point timeframe:

One Month post Dose 1, at Month 1 [PI(M1)]

Notes:

[18] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

[19] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting values for the SB692342 2 dose Group, the SB692342 1 dose Group and the Control Menjugate Group from the baseline period.

End point values	SB692342 2 dose Group	SB692342 1 dose Group	Control Menjugate Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	50	50	50	
Units: Subjects				
Haem, PI(M1), Grade 3	0	0	0	
WBC, PI(M1) Grade 3	0	0	0	
PLA, PI(M1), Grade 3	0	0	0	
ALA, PI(M1), Grade 3	0	0	0	
CREA PI(M1), Grade 3	0	0	0	

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of subjects with grade 3 haematological and biochemical levels

End point title	Number of subjects with grade 3 haematological and biochemical levels <sup>[20][21]</sup>
-----------------	---

End point description:

Haematological/Biochemical parameters assessed were: Haemoglobin (Haem), White Blood Cells (WBC), Platelets (PLA), Alanine Aminotransferase (ALA) and Creatinine (CREA). Grade 3 = Haem.: < 5.0 g/dL; WBC.: 1.0 to 1.4 x 10<sup>3</sup>/μL; PLA.: < 25x10<sup>3</sup>/μL; ALA.: 5.1 to 10.0 x ULN and CREA: 3.1 to 6.0 x ULN.

End point type	Primary
----------------	---------

End point timeframe:

One Month post Dose 2, at Month 2 [PII(M2)]

Notes:

[20] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

[21] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting values for the SB692342 2 dose Group and the Control Menjugate Group from the baseline period.

End point values	SB692342 2 dose Group	Control Menjugate Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	50	50		
Units: Subjects				
Haem, PII(M2), Grade 3	0	0		
WBC, PII(M2) Grade 3	0	0		
PLA, PII(M2), Grade 3	0	0		
ALA, PII(M2), Grade 3	0	0		
CREA PII(M2), Grade 3	0	0		

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of subjects with grade 3 haematological and biochemical levels

End point title	Number of subjects with grade 3 haematological and biochemical levels <sup>[22]</sup>
-----------------	---

End point description:

Haematological/Biochemical parameters assessed were: Haemoglobin (Haem), White Blood Cells (WBC),

Platelets (PLA), Alanine Aminotransferase (ALA) and Creatinine (CREA). Grade 3 = Haem.: < 5.0 g/dL; WBC.: 1.0 to 1.4 x 10<sup>3</sup>/μL; PLA.: < 25x10<sup>3</sup>/μL; ALA.: 5.1 to 10.0 x ULN and CREA: 3.1 to 6.0 x ULN.

End point type	Primary
End point timeframe:	
One Month post Dose 3, at Month 3 [PIII(M3)]	

Notes:

[22] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	SB692392 2 dose + Tritanrix + Pevnar + Polio Sabin Group	SB692392 1 dose + Tritanrix + Pevnar + Polio Sabin Group	Control Tritanrix + Pevnar + Polio Sabin Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	49	52	49	
Units: Subjects				
Haem, PIII(M3), Grade 3	0	0	0	
WBC, PIII(M3) Grade 3	0	0	0	
PLA, PIII(M3), Grade 3	0	0	0	
ALA, PIII(M3), Grade 3	0	0	0	
CREA PIII(M3), Grade 3	0	0	0	

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of subjects with grade 3 haematological and biochemical levels

End point title	Number of subjects with grade 3 haematological and biochemical levels <sup>[23]</sup> <sup>[24]</sup>
-----------------	---

End point description:

Haematological/Biochemical parameters assessed were: Haemoglobin (Haem), White Blood Cells (WBC), Platelets (PLA), Alanine Aminotransferase (ALA) and Creatinine (CREA). Grade 3 = Haem.: < 5.0 g/dL; WBC.: 1.0 to 1.4 x 10<sup>3</sup>/μL; PLA.: < 25x10<sup>3</sup>/μL; ALA.: 5.1 to 10.0 x ULN and CREA: 3.1 to 6.0 x ULN.

End point type	Primary
End point timeframe:	
Six Months post Dose 1, at Month 6 [PI(M6)]	

Notes:

[23] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

[24] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting values for the SB692342 1 dose Group from the baseline period.

<b>End point values</b>	SB692342 1 dose Group			
Subject group type	Reporting group			
Number of subjects analysed	50			
Units: Subjects				
Haem, PI(M6), Grade 3	0			
WBC, PI(M6) Grade 3	0			
PLA, PI(M6), Grade 3	0			
ALA, PI(M6), Grade 3	0			
CREA PI(M6), Grade 3	0			

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of subjects with grade 3 haematological and biochemical levels

End point title	Number of subjects with grade 3 haematological and biochemical levels <sup>[25]</sup> <sup>[26]</sup>
-----------------	---

End point description:

Haematological/Biochemical parameters assessed were: Haemoglobin (Haem), White Blood Cells (WBC), Platelets (PLA), Alanine Aminotransferase (ALA) and Creatinine (CREA). Grade 3 = Haem.: < 5.0 g/dL; WBC.: 1.0 to 1.4 x 10<sup>3</sup>/μL; PLA.: < 25x10<sup>3</sup>/μL; ALA.: 5.1 to 10.0 x ULN and CREA: 3.1 to 6.0 x ULN.

End point type	Primary
----------------	---------

End point timeframe:

Six Months post Dose 2, at Month 7 [PII(M7)]

Notes:

[25] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

[26] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting values for the SB692342 2 dose Group and the Control Menjugate Group from the baseline period.

<b>End point values</b>	SB692342 2 dose Group	Control Menjugate Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	50	50		
Units: Subjects				
Haem, PII(M7), Grade 3	0	0		
WBC, PII(M7) Grade 3	0	0		
PLA, PII(M7), Grade 3	0	0		
ALA, PII(M7), Grade 3	0	0		
CREA PII(M7), Grade 3	0	0		

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of subjects with grade 3 haematological and biochemical levels

End point title	Number of subjects with grade 3 haematological and biochemical levels <sup>[27][28]</sup>
-----------------	---

End point description:

Haematological/Biochemical parameters assessed were: Haemoglobin (Haem), White Blood Cells (WBC), Platelets (PLA), Alanine Aminotransferase (ALA) and Creatinine (CREA). Grade 3 = Haem.: < 5.0 g/dL; WBC.: 1.0 to 1.4 x 10<sup>3</sup>/μL; PLA.: < 25x10<sup>3</sup>/μL; ALA.: 5.1 to 10.0 x ULN and CREA: 3.1 to 6.0 x ULN.

End point type	Primary
----------------	---------

End point timeframe:

Six Months post Dose 3, at Month 13 [PIII(M13)]

Notes:

[27] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

[28] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting values for the SB692342 2 dose Group and the Control Menjugate Group from the baseline period.

End point values	SB692342 2 dose Group	Control Menjugate Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	50	50		
Units: Subjects				
Haem, PIII(M13), Grade 3	0	0		
WBC, PIII(M13) Grade 3	0	0		
PLA, PIII(M13), Grade 3	0	0		
ALA, PIII(M13), Grade 3	0	0		
CREA PIII(M13), Grade 3	0	0		

### Statistical analyses

No statistical analyses for this end point

### Primary: Number of subjects with grade 3 haematological and biochemical levels

End point title	Number of subjects with grade 3 haematological and biochemical levels <sup>[29][30]</sup>
-----------------	---

End point description:

Haematological/Biochemical parameters assessed were: Haemoglobin (Haem), White Blood Cells (WBC), Platelets (PLA), Alanine Aminotransferase (ALA) and Creatinine (CREA). Grade 3 = Haem.: < 5.0 g/dL; WBC.: 1.0 to 1.4 x 10<sup>3</sup>/μL; PLA.: < 25x10<sup>3</sup>/μL; ALA.: 5.1 to 10.0 x ULN and CREA: 3.1 to 6.0 x ULN.

End point type	Primary
----------------	---------

End point timeframe:

Twelve Months post Dose 1, at Month 12 [PI(M12)]

Notes:

[29] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

[30] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting values for the SB692342 2 dose Group from the baseline period.

End point values	SB692342 2 dose Group			
Subject group type	Reporting group			
Number of subjects analysed	50			
Units: Subjects				
Haem, PI(M12), Grade 3	0			
WBC, PI(M12) Grade 3	0			
PLA, PI(M12), Grade 3	0			
ALA, PI(M12), Grade 3	0			
CREA PI(M12), Grade 3	0			

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of subjects with grade 3 haematological and biochemical levels

End point title	Number of subjects with grade 3 haematological and biochemical levels <sup>[31]</sup> <sup>[32]</sup>
-----------------	---

End point description:

Haematological/Biochemical parameters assessed were: Haemoglobin (Haem), White Blood Cells (WBC), Platelets (PLA), Alanine Aminotransferase (ALA) and Creatinine (CREA). Grade 3 = Haem.: < 5.0 g/dL; WBC.: 1.0 to 1.4 x 10<sup>3</sup>/μL; PLA.: < 25x10<sup>3</sup>/μL; ALA.: 5.1 to 10.0 x ULN and CREA: 3.1 to 6.0 x ULN.

End point type	Primary
----------------	---------

End point timeframe:

Twelve Months post Dose 2, at Month 13 [PII(M13)]

Notes:

[31] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

[32] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting values for the SB692342 2 dose Group and the Control Menjugate Group from the baseline period.

End point values	SB692342 2 dose Group	Control Menjugate Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	50	50		
Units: Subjects				
Haem, PII(M13), Grade 3	0	0		

WBC, PII(M13) Grade 3	0	0		
PLA, PII(M13), Grade 3	0	0		
ALA, PII(M13), Grade 3	0	0		
CREA PII(M13), Grade 3	0	0		

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of subjects with grade 3 haematological and biochemical levels

End point title	Number of subjects with grade 3 haematological and biochemical levels <sup>[33]</sup>
-----------------	---

End point description:

Haematological/Biochemical parameters assessed were: Haemoglobin (Haem), White Blood Cells (WBC), Platelets (PLA), Alanine Aminotransferase (ALA) and Creatinine (CREA). Grade 3 = Haem.: < 5.0 g/dL; WBC.: 1.0 to 1.4 x 10<sup>3</sup>/μL; PLA.: < 25x10<sup>3</sup>/μL; ALA.: 5.1 to 10.0 x ULN and CREA: 3.1 to 6.0 x ULN.

End point type	Primary
----------------	---------

End point timeframe:

Twelve Months post Dose 3, at Month 14 [PIII(M14)]

Notes:

[33] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	SB692392 2 dose + Tritanrix + Pevnar + Polio Sabin Group	SB692392 1 dose + Tritanrix + Pevnar + Polio Sabin Group	Control Tritanrix + Pevnar + Polio Sabin Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	49	52	49	
Units: Subjects				
Haem, PIII(M14), Grade 3	0	0	0	
WBC, PIII(M14) Grade 3	0	0	0	
PLA, PIII(M14), Grade 3	0	0	1	
ALA, PIII(M14), Grade 3	0	0	0	
CREA PIII(M14), Grade 3	0	0	0	

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of subjects with grade 3 haematological and biochemical levels

End point title	Number of subjects with grade 3 haematological and biochemical levels <sup>[34]</sup>
-----------------	---

End point description:

Haematological/Biochemical parameters assessed were: Haemoglobin (Haem), White Blood Cells (WBC), Platelets (PLA), Alanine Aminotransferase (ALA) and Creatinine (CREA). Grade 3 = Haem.: < 5.0 g/dL; WBC.: 1.0 to 1.4 x 10<sup>3</sup>/μL; PLA.: < 25x10<sup>3</sup>/μL; ALA.: 5.1 to 10.0 x ULN and CREA: 3.1 to 6.0 x ULN.



End point type	Primary
End point timeframe:	
Six Months post Dose 3, at Month 8 [PIII(M8)]	
Notes:	
[34] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.	
Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.	

End point values	SB692392 2 dose + Tritanrix + Pevnar + Polio Sabin Group	SB692392 1 dose + Tritanrix + Pevnar + Polio Sabin Group	Control Tritanrix + Pevnar + Polio Sabin Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	49	50	49	
Units: Subjects				
Haem, PIII(M8), Grade 3	0	0	0	
WBC, PIII(M8) Grade 3	0	0	0	
PLA, PIII(M8), Grade 3	0	0	0	
ALA, PIII(M8), Grade 3	0	1	0	
CREA PIII(M8), Grade 3	0	0	0	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Frequency of M. tuberculosis fusion protein M72 (M72)-specific cluster of differentiation (CD)4+ T cells per million cells expressing at least two different immune markers

End point title	Frequency of M. tuberculosis fusion protein M72 (M72)-specific cluster of differentiation (CD)4+ T cells per million cells expressing at least two different immune markers <sup>[35]</sup>
-----------------	---

End point description:

Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (INF-γ), Tumour necrosis factor-alpha (TNF-α) and CD40-ligand (CD40-L).

End point type	Secondary
End point timeframe:	
Before vaccination (PRE)	

Notes:

[35] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting values for the SB692342 2 dose Group, the SB692342 1 dose Group and the Control Menjugate Group from the baseline period.

End point values	SB692342 2 dose Group	SB692392 2 dose + Tritanrix + Pevnar + Polio Sabin Group	SB692342 1 dose Group	SB692392 1 dose + Tritanrix + Pevnar + Polio Sabin Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	37	36	42	39
Units: T cells/million cells				

median (inter-quartile range (Q1-Q3))				
CD4 all doubles, PRE	47 (23 to 87)	59.5 (30.5 to 125)	42.5 (22 to 71)	88 (27 to 181)
CD4.CD40-L(+)+IL-2(+)+TNF- $\alpha$ (+)+INF- $\gamma$ (+), PRE	1 (1 to 1)	1 (1 to 24.5)	1 (1 to 12)	14 (1 to 53)
CD4.CD40-L(+)+IL-2(+)+TNF- $\alpha$ (+)+INF- $\gamma$ (-), PRE	1 (1 to 12)	1 (1 to 12)	1 (1 to 1)	1 (1 to 17)
CD4.CD40-L(+)+IL-2(+)+TNF- $\alpha$ (-)+INF- $\gamma$ (+), PRE	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 13)
CD4.CD40-L(+)+IL-2(+)+TNF- $\alpha$ (-)+INF- $\gamma$ (-), PRE	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD4.CD40-L(+)+IL-2(-)+TNF- $\alpha$ (+)+INF- $\gamma$ (+), PRE	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD4.CD40-L(+)+IL-2(-)+TNF- $\alpha$ (+)+INF- $\gamma$ (-), PRE	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD4.CD40-L(+)+IL-2(-)+TNF- $\alpha$ (-)+INF- $\gamma$ (+), PRE	1 (1 to 11)	1 (1 to 13)	1 (1 to 1)	1 (1 to 15)
CD4.CD40-L(+)+IL-2(-)+TNF- $\alpha$ (-)+INF- $\gamma$ (-), PRE	14 (1 to 51)	1 (1 to 28)	11.5 (1 to 41)	3 (1 to 62)
CD4.CD40-L(-)+IL-2(+)+TNF- $\alpha$ (+)+INF- $\gamma$ (+), PRE	1 (1 to 12)	1 (1 to 24)	1 (1 to 12)	1 (1 to 27)
CD4.CD40-L(-)+IL-2(+)+TNF- $\alpha$ (+)+INF- $\gamma$ (-), PRE	1 (1 to 12)	1 (1 to 6)	1 (1 to 12)	1 (1 to 1)
CD4.CD40-L(-)+IL-2(+)+TNF- $\alpha$ (-)+INF- $\gamma$ (+), PRE	1 (1 to 1)	1 (1 to 11.5)	1 (1 to 1)	1 (1 to 20)
CD4.CD40-L(-)+IL-2(+)+TNF- $\alpha$ (-)+INF- $\gamma$ (-), PRE	1 (1 to 38)	5.5 (1 to 29.5)	1 (1 to 40)	28 (1 to 63)
CD4.CD40-L(-)+IL-2(-)+TNF- $\alpha$ (+)+INF- $\gamma$ (+), PRE	1 (1 to 1)	1 (1 to 12.5)	1 (1 to 1)	1 (1 to 1)
CD4.CD40-L(-)+IL-2(-)+TNF- $\alpha$ (+)+INF- $\gamma$ (-), PRE	1 (1 to 11)	1 (1 to 27.5)	1 (1 to 19)	1 (1 to 11)
CD4.CD40-L(-)+IL-2(-)+TNF- $\alpha$ (-)+INF- $\gamma$ (+), PRE	1 (1 to 11)	1 (1 to 21.5)	1 (1 to 13)	12 (1 to 47)

End point values	Control Menjugate Group	Control Tritanrix + Prevnar + Polio Sabin Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	34	39		
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD4 all doubles, PRE	44.5 (11 to 65)	52 (33 to 149)		
CD4.CD40-L(+)+IL-2(+)+TNF- $\alpha$ (+)+INF- $\gamma$ (+), PRE	1 (1 to 15)	1 (1 to 30)		
CD4.CD40-L(+)+IL-2(+)+TNF- $\alpha$ (+)+INF- $\gamma$ (-), PRE	1 (1 to 1)	1 (1 to 14)		
CD4.CD40-L(+)+IL-2(+)+TNF- $\alpha$ (-)+INF- $\gamma$ (+), PRE	1 (1 to 1)	1 (1 to 1)		
CD4.CD40-L(+)+IL-2(+)+TNF- $\alpha$ (-)+INF- $\gamma$ (-), PRE	1 (1 to 1)	1 (1 to 1)		
CD4.CD40-L(+)+IL-2(-)+TNF- $\alpha$ (+)+INF- $\gamma$ (+), PRE	1 (1 to 1)	1 (1 to 1)		
CD4.CD40-L(+)+IL-2(-)+TNF- $\alpha$ (+)+INF- $\gamma$ (-), PRE	1 (1 to 1)	1 (1 to 1)		
CD4.CD40-L(+)+IL-2(-)+TNF- $\alpha$ (-)+INF- $\gamma$ (+), PRE	1 (1 to 1)	1 (1 to 13)		

CD4.CD40-L(+)+IL-2(-)+TNF-α (-) )+INF-γ (-), PRE	1 (1 to 16)	1 (1 to 52)		
CD4.CD40-L(-)+IL-2(+)+TNF-α(+)+INF-γ (+), PRE	1 (1 to 1)	1 (1 to 27)		
CD4.CD40-L(-)+IL-2(+)+TNF-α(+)+INF-γ (-), PRE	1 (1 to 11)	1 (1 to 16)		
CD4.CD40-L(-)+IL-2(+)+TNF-α (-) )+INF-γ (+), PRE	1 (1 to 1)	1 (1 to 15)		
CD4.CD40-L(-)+IL-2(+)+TNF-α (-) )+INF-γ (-), PRE	1 (1 to 40)	20 (1 to 62)		
CD4.CD40-L(-)+IL-2(-)+TNF-α (+)+INF-γ(+), PRE	1 (1 to 1)	1 (1 to 1)		
CD4.CD40-L(-)+IL-2(-)+TNF-α (+)+INF-γ (-), PRE	1.5 (1 to 14)	1 (1 to 21)		
CD4.CD40-L(-)+IL-2(-)+TNF-α (-)+INF-γ(+), PRE	1 (1 to 22)	15 (1 to 49)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Frequency of M. tuberculosis fusion protein M72 (M72)-specific cluster of differentiation (CD)4+ T cells per million cells expressing at least two different immune markers

End point title	Frequency of M. tuberculosis fusion protein M72 (M72)-specific cluster of differentiation (CD)4+ T cells per million cells expressing at least two different immune markers <sup>[36]</sup>
-----------------	---

End point description:

Immune markers expressed were among Interleukin-2 (IL-2) and/or Interferon-gamma (INF-γ) and/or Tumour necrosis factor-alpha (TNF-α) and/or CD40-ligand (CD40-L).

End point type	Secondary
----------------	-----------

End point timeframe:

Seven Days post each dose (D7)

Notes:

[36] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting values for the SB692342 2 dose Group, the SB692342 1 dose Group and the Control Menjugate Group from the baseline period.

End point values	SB692342 2 dose Group	SB692392 2 dose + Tritanrix + Prevnar + Polio Sabin Group	SB692342 1 dose Group	SB692392 1 dose + Tritanrix + Prevnar + Polio Sabin Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	37	42	43	43
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD4 all doubles, D7	499 (250 to 1267)	593.5 (269 to 1094)	128 (83 to 379)	174 (67 to 321)
CD4.CD40-L(+)+IL-2(+)+TNF-α(+)+INF-γ (+), D7	24 (1 to 83)	42.5 (14 to 66)	1 (1 to 39)	16 (1 to 43)
CD4.CD40-L(+)+IL-2(+)+TNF-α(+)+INF-γ (-), D7	47 (15 to 143)	61.5 (18 to 157)	12 (1 to 25)	12 (1 to 29)
CD4.CD40-L(+)+IL-2(+)+TNF-α (-)+INF-γ (+), D7	25 (1 to 103)	19.5 (1 to 71)	1 (1 to 26)	13 (1 to 38)

CD4.CD40-L(+)+IL-2(+)+TNF-α (-)+I INF-γ (-), D7	65 (12 to 286)	82.5 (29 to 320)	24 (1 to 52)	14 (1 to 44)
CD4.CD40-L(+)+IL-2(-)+TNF- α(+)+INF-γ (+), D7	1 (1 to 15)	1 (1 to 22)	1 (1 to 1)	1 (1 to 12)
CD4.CD40-L(+)+IL-2(-)+TNF- α(+)+INF-γ (-), D7	1 (1 to 32)	11 (1 to 38)	1 (1 to 11)	1 (1 to 1)
CD4.CD40-L(+)+IL-2(-)+TNF-α (- ) +INF-γ (+), D7	19 (9 to 61)	36.5 (1 to 105)	1 (1 to 19)	13 (1 to 49)
CD4.CD40-L(+)+IL-2(-)+TNF-α (- ) +INF-γ (-), D7	52 (1 to 144)	112 (25 to 297)	24 (1 to 102)	21 (1 to 58)
CD4.CD40-L(-)+IL-2(+)+TNF- α(+)+INF-γ (+), D7	12 (1 to 32)	14.5 (1 to 45)	1 (1 to 24)	1 (1 to 21)
CD4.CD40-L(-)+IL-2(+)+TNF- α(+)+INF-γ (-), D7	64 (12 to 107)	35.5 (1 to 88)	3 (1 to 24)	1 (1 to 13)
CD4.CD40-L(-)+IL-2(+)+TNF-α (- ) +INF-γ (+), D7	173 (38 to 232)	102 (31 to 237)	22 (1 to 86)	22 (1 to 67)
CD4.CD40-L(-)+IL-2(+)+TNF-α (- ) +INF-γ (-), D7	576 (245 to 1126)	493 (309 to 960)	138 (42 to 208)	26 (1 to 134)
CD4.CD40-L(-)+IL-2(-)+TNF-α (+) +INF-γ(+), D7	1 (1 to 18)	1 (1 to 36)	1 (1 to 11)	1 (1 to 13)
CD4.CD40-L(-)+IL-2(-)+TNF-α (+) +INF-γ (-), D7	25 (10 to 58)	27.5 (5 to 85)	1 (1 to 28)	1 (1 to 20)
CD4.CD40-L(-)+IL-2(-)+TNF-α (-)+INF- γ(+), D7	232 (85 to 444)	160.5 (61 to 314)	30 (5 to 69)	40 (12 to 91)

<b>End point values</b>	Control Menjugate Group	Control Tritanrix + Prevnar + Polio Sabin Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	37	44		
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD4 all doubles, D7	55 (33 to 81)	52.5 (33 to 85)		
CD4.CD40-L(+)+IL-2(+)+TNF- α(+)+INF-γ (+), D7	1 (1 to 15)	1 (1 to 19)		
CD4.CD40-L(+)+IL-2(+)+TNF- α(+)+INF-γ (-), D7	1 (1 to 12)	1 (1 to 1)		
CD4.CD40-L(+)+IL-2(+)+TNF-α (- ) +INF-γ (+), D7	1 (1 to 1)	1 (1 to 1)		
CD4.CD40-L(+)+IL-2(+)+TNF-α (-)+I INF-γ (-), D7	1 (1 to 1)	1 (1 to 1)		
CD4.CD40-L(+)+IL-2(-)+TNF- α(+)+INF-γ (+), D7	1 (1 to 1)	1 (1 to 1)		
CD4.CD40-L(+)+IL-2(-)+TNF- α(+)+INF-γ (-), D7	1 (1 to 1)	1 (1 to 1)		
CD4.CD40-L(+)+IL-2(-)+TNF-α (- ) +INF-γ (+), D7	1 (1 to 1)	1 (1 to 13)		
CD4.CD40-L(+)+IL-2(-)+TNF-α (- ) +INF-γ (-), D7	9 (1 to 63)	1 (1 to 37)		
CD4.CD40-L(-)+IL-2(+)+TNF- α(+)+INF-γ (+), D7	1 (1 to 12)	11.5 (1 to 15.5)		
CD4.CD40-L(-)+IL-2(+)+TNF- α(+)+INF-γ (-), D7	1 (1 to 13)	1 (1 to 7.5)		
CD4.CD40-L(-)+IL-2(+)+TNF-α (- ) +INF-γ (+), D7	1 (1 to 1)	1 (1 to 14.5)		
CD4.CD40-L(-)+IL-2(+)+TNF-α (- ) +INF-γ (-), D7	1 (1 to 45)	1 (1 to 42.5)		

CD4.CD40-L(-)+IL-2(-)+TNF-α (+)+INF-γ(+), D7	1 (1 to 1)	1 (1 to 1)		
CD4.CD40-L(-)+IL-2(-)+TNF-α (+)+INF-γ (-), D7	11 (1 to 21)	1 (1 to 13.5)		
CD4.CD40-L(-)+IL-2(-)+TNF-α (-)+INF-γ(+), D7	1 (1 to 17)	14 (1 to 44.5)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Frequency of M. tuberculosis fusion protein M72 (M72)-specific cluster of differentiation (CD)4+ T cells per million cells expressing at least two different immune markers

End point title	Frequency of M. tuberculosis fusion protein M72 (M72)-specific cluster of differentiation (CD)4+ T cells per million cells expressing at least two different immune markers <sup>[37]</sup>
-----------------	---

End point description:

Immune markers expressed were among Interleukin-2 (IL-2) and/or Interferon-gamma (INF-γ) and/or Tumour necrosis factor-alpha (TNF-α) and/or CD40-ligand (CD40-L).

End point type	Secondary
----------------	-----------

End point timeframe:

One Month post each dose (M1)

Notes:

[37] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting values for the SB692342 2 dose Group, the SB692342 1 dose Group and the Control Menjugate Group from the baseline period.

End point values	SB692342 2 dose Group	SB692392 2 dose + Tritanrix + Pevnar + Polio Sabin Group	SB692342 1 dose Group	SB692392 1 dose + Tritanrix + Pevnar + Polio Sabin Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	41	43	44	41
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD4 all doubles, M1	640 (403 to 1200)	859 (348 to 1950)	173.5 (93.5 to 476)	235 (142 to 485)
CD4.CD40-L(+)+IL-2(+)+TNF-α(+)+INF-γ (+), M1	52 (1 to 157)	50 (12 to 253)	17 (1 to 63)	25 (1 to 88)
CD4.CD40-L(+)+IL-2(+)+TNF-α(+)+INF-γ (-), M1	142 (48 to 300)	195 (66 to 408)	30 (11.5 to 82.5)	56 (14 to 88)
CD4.CD40-L(+)+IL-2(+)+TNF-α (-)+INF-γ (+), M1	14 (1 to 45)	24 (1 to 132)	1 (1 to 14)	12 (1 to 26)
CD4.CD40-L(+)+IL-2(+)+TNF-α (-)+INF-γ (-), M1	109 (49 to 143)	138 (56 to 327)	27 (1 to 59)	28 (12 to 63)
CD4.CD40-L(+)+IL-2(-)+TNF-α(+)+INF-γ (+), M1	1 (1 to 19)	17 (1 to 37)	1 (1 to 1)	1 (1 to 12)
CD4.CD40-L(+)+IL-2(-)+TNF-α(+)+INF-γ (-), M1	15 (1 to 44)	14 (1 to 63)	1 (1 to 6)	1 (1 to 1)
CD4.CD40-L(+)+IL-2(-)+TNF-α (-)+INF-γ (+), M1	14 (1 to 41)	24 (1 to 64)	1 (1 to 12)	12 (1 to 24)
CD4.CD40-L(+)+IL-2(-)+TNF-α (-)+INF-γ (-), M1	51 (1 to 107)	51 (1 to 162)	1 (1 to 50.5)	16 (1 to 96)

CD4.CD40-L(-)+IL-2(+)+TNF- α(+)+INF-γ (+), M1	28 (1 to 109)	20 (1 to 60)	1 (1 to 45)	12 (1 to 24)
CD4.CD40-L(-)+IL-2(+)+TNF- α(+)+INF-γ (-), M1	95 (32 to 251)	127 (63 to 257)	28 (1 to 59.5)	15 (1 to 78)
CD4.CD40-L(-)+IL-2(+)+TNF-α (- ) +INF-γ (+), M1	57 (26 to 204)	63 (27 to 118)	19 (1 to 76)	24 (1 to 44)
CD4.CD40-L(-)+IL-2(+)+TNF-α (- ) +INF-γ (-), M1	431 (239 to 838)	449 (253 to 793)	115.5 (42.5 to 277.5)	127 (36 to 257)
CD4.CD40-L(-)+IL-2(-)+TNF-α (+) +INF-γ(+), M1	1 (1 to 27)	1 (1 to 29)	1 (1 to 7)	1 (1 to 1)
CD4.CD40-L(-)+IL-2(-)+TNF-α (+) +INF-γ (-), M1	53 (5 to 106)	51 (3 to 108)	9.5 (1 to 38)	19 (1 to 58)
CD4.CD40-L(-)+IL-2(-)+TNF-α (-)+INF- γ(+), M1	54 (18 to 107)	71 (25 to 141)	19.5 (1 to 49)	11 (1 to 48)

End point values	Control Menjugate Group	Control Tritanrix + Prevnam + Polio Sabin Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	34	42		
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD4 all doubles, M1	31 (22 to 66)	55.5 (30 to 115)		
CD4.CD40-L(+)+IL-2(+)+TNF- α(+)+INF-γ (+), M1	1 (1 to 12)	12 (1 to 26)		
CD4.CD40-L(+)+IL-2(+)+TNF- α(+)+INF-γ (-), M1	1 (1 to 12)	1 (1 to 17)		
CD4.CD40-L(+)+IL-2(+)+TNF-α (- ) +INF-γ (+), M1	1 (1 to 1)	1 (1 to 1)		
CD4.CD40-L(+)+IL-2(+)+TNF-α (-)+I INF-γ (-), M1	1 (1 to 1)	1 (1 to 12)		
CD4.CD40-L(+)+IL-2(-)+TNF- α(+)+INF-γ (+), M1	1 (1 to 1)	1 (1 to 11)		
CD4.CD40-L(+)+IL-2(-)+TNF- α(+)+INF-γ (-), M1	1 (1 to 1)	1 (1 to 12)		
CD4.CD40-L(+)+IL-2(-)+TNF-α (- ) +INF-γ (+), M1	1 (1 to 1)	1 (1 to 14)		
CD4.CD40-L(+)+IL-2(-)+TNF-α (- ) +INF-γ (-), M1	1 (1 to 42)	1 (1 to 42)		
CD4.CD40-L(-)+IL-2(+)+TNF- α(+)+INF-γ (+), M1	1 (1 to 1)	1 (1 to 15)		
CD4.CD40-L(-)+IL-2(+)+TNF- α(+)+INF-γ (-), M1	1 (1 to 1)	1 (1 to 1)		
CD4.CD40-L(-)+IL-2(+)+TNF-α (- ) +INF-γ (+), M1	1 (1 to 1)	1 (1 to 1)		
CD4.CD40-L(-)+IL-2(+)+TNF-α (- ) +INF-γ (-), M1	3 (1 to 33)	23 (1 to 66)		
CD4.CD40-L(-)+IL-2(-)+TNF-α (+) +INF-γ(+), M1	1 (1 to 1)	1 (1 to 1)		
CD4.CD40-L(-)+IL-2(-)+TNF-α (+) +INF-γ (-), M1	1 (1 to 15)	11 (1 to 35)		
CD4.CD40-L(-)+IL-2(-)+TNF-α (-)+INF- γ(+), M1	1 (1 to 14)	1 (1 to 21)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Frequency of M. tuberculosis fusion protein M72 (M72)-specific cluster of differentiation (CD)4+ T cells per million cells expressing at least two different immune markers

End point title	Frequency of M. tuberculosis fusion protein M72 (M72)-specific cluster of differentiation (CD)4+ T cells per million cells expressing at least two different immune markers <sup>[38]</sup>
-----------------	---

End point description:

Immune markers expressed were among Interleukin-2 (IL-2) and/or Interferon-gamma (INF-γ) and/or Tumour necrosis factor-alpha (TNF-α) and/or CD40-ligand (CD40-L).

End point type	Secondary
----------------	-----------

End point timeframe:

Six Months post each dose (M6)

Notes:

[38] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting values for the SB692342 2 dose Group, the SB692342 1 dose Group and the Control Menjugate Group from the baseline period.

End point values	SB692342 2 dose Group	SB692392 2 dose + Tritanrix + Prevnar + Polio Sabin Group	SB692342 1 dose Group	SB692392 1 dose + Tritanrix + Prevnar + Polio Sabin Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	36	40	42	43
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD4 all doubles, M6	633 (324 to 1062)	512 (318.5 to 992.5)	107.5 (47 to 184)	107 (72 to 191)
CD4.CD40-L(+)+IL-2(+)+TNF-α(+)+INF-γ (+), M6	63 (18.5 to 129)	65 (13 to 125)	12 (1 to 28)	16 (1 to 48)
CD4.CD40-L(+)+IL-2(+)+TNF-α(+)+INF-γ (-), M6	223 (78 to 403)	202.5 (101.5 to 434)	28 (1 to 50)	17 (1 to 64)
CD4.CD40-L(+)+IL-2(+)+TNF-α (-)+INF-γ (+), M6	18.5 (1 to 25.5)	15.5 (1 to 29)	1 (1 to 1)	1 (1 to 13)
CD4.CD40-L(+)+IL-2(+)+TNF-α (-)+INF-γ (-), M6	68.5 (40.5 to 163)	65 (34.5 to 184.5)	1 (1 to 22)	13 (1 to 41)
CD4.CD40-L(+)+IL-2(-)+TNF-α(+)+INF-γ (+), M6	1 (1 to 1)	1 (1 to 13)	1 (1 to 1)	1 (1 to 1)
CD4.CD40-L(+)+IL-2(-)+TNF-α(+)+INF-γ (-), M6	12 (1 to 20.5)	1 (1 to 26)	1 (1 to 11)	1 (1 to 1)
CD4.CD40-L(+)+IL-2(-)+TNF-α (-)+INF-γ (+), M6	1 (1 to 6.5)	1 (1 to 28)	1 (1 to 1)	1 (1 to 1)
CD4.CD40-L(+)+IL-2(-)+TNF-α (-)+INF-γ (-), M6	16.5 (1 to 71)	40.5 (1 to 95.5)	1 (1 to 28)	2 (1 to 44)
CD4.CD40-L(-)+IL-2(+)+TNF-α(+)+INF-γ (+), M6	13.5 (1 to 59.5)	13 (1 to 52.5)	1 (1 to 14)	1 (1 to 17)

CD4.CD40-L(-)+IL-2(+)+TNF- α(+)+INF-γ (-), M6	72 (38 to 206.5)	86.5 (27 to 156.5)	12 (1 to 28)	5 (1 to 40)
CD4.CD40-L(-)+IL-2(+)+TNF-α (- ) +INF-γ (+), M6	31 (1 to 84.5)	26 (7 to 55)	1 (1 to 13)	1 (1 to 16)
CD4.CD40-L(-)+IL-2(+)+TNF-α (- ) +INF-γ (-), M6	310.5 (60 to 591.5)	171.5 (126.5 to 369)	35.5 (1 to 68)	48 (8 to 99)
CD4.CD40-L(-)+IL-2(-)+TNF-α (+) +INF-γ(+), M6	1 (1 to 18)	1 (1 to 13)	1 (1 to 1)	1 (1 to 1)
CD4.CD40-L(-)+IL-2(-)+TNF-α (+) +INF-γ (-), M6	19 (1 to 71.5)	27 (1 to 61)	1 (1 to 12)	1 (1 to 14)
CD4.CD40-L(-)+IL-2(-)+TNF-α (-)+INF- γ(+), M6	19.5 (1 to 58)	14 (1 to 46.5)	1 (1 to 14)	1 (1 to 16)

End point values	Control Menjugate Group	Control Tritanrix + Prevnar + Polio Sabin Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	34	44		
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD4 all doubles, M6	39 (23 to 71)	41 (23 to 73.5)		
CD4.CD40-L(+)+IL-2(+)+TNF- α(+)+INF-γ (+), M6	1 (1 to 13)	1 (1 to 13.5)		
CD4.CD40-L(+)+IL-2(+)+TNF- α(+)+INF-γ (-), M6	1 (1 to 15)	1 (1 to 12.5)		
CD4.CD40-L(+)+IL-2(+)+TNF-α (- ) +INF-γ (+), M6	1 (1 to 1)	1 (1 to 1)		
CD4.CD40-L(+)+IL-2(+)+TNF-α (-)+I INF-γ (-), M6	1 (1 to 1)	1 (1 to 1)		
CD4.CD40-L(+)+IL-2(-)+TNF- α(+)+INF-γ (+), M6	1 (1 to 1)	1 (1 to 1)		
CD4.CD40-L(+)+IL-2(-)+TNF- α(+)+INF-γ (-), M6	1 (1 to 1)	1 (1 to 1)		
CD4.CD40-L(+)+IL-2(-)+TNF-α (- ) +INF-γ (+), M6	1 (1 to 11)	1 (1 to 13)		
CD4.CD40-L(+)+IL-2(-)+TNF-α (- ) +INF-γ (-), M6	1 (1 to 39)	13.5 (1 to 48.5)		
CD4.CD40-L(-)+IL-2(+)+TNF- α(+)+INF-γ (+), M6	1 (1 to 1)	1 (1 to 1)		
CD4.CD40-L(-)+IL-2(+)+TNF- α(+)+INF-γ (-), M6	1 (1 to 13)	1 (1 to 1)		
CD4.CD40-L(-)+IL-2(+)+TNF-α (- ) +INF-γ (+), M6	1 (1 to 1)	1 (1 to 1)		
CD4.CD40-L(-)+IL-2(+)+TNF-α (- ) +INF-γ (-), M6	10 (1 to 27)	12.5 (1 to 41)		
CD4.CD40-L(-)+IL-2(-)+TNF-α (+) +INF-γ(+), M6	1 (1 to 1)	1 (1 to 1)		
CD4.CD40-L(-)+IL-2(-)+TNF-α (+) +INF-γ (-), M6	1 (1 to 14)	1 (1 to 13.5)		
CD4.CD40-L(-)+IL-2(-)+TNF-α (-)+INF- γ(+), M6	1 (1 to 18)	1 (1 to 14)		

## Statistical analyses



**Secondary: Frequency of M. tuberculosis fusion protein M72 (M72)-specific cluster of differentiation (CD)4+ T cells per million cells expressing at least two different immune markers**

End point title	Frequency of M. tuberculosis fusion protein M72 (M72)-specific cluster of differentiation (CD)4+ T cells per million cells expressing at least two different immune markers <sup>[39]</sup>
-----------------	---

End point description:

Immune markers expressed were among Interleukin-2 (IL-2) and/or Interferon-gamma (INF-γ) and/or Tumour necrosis factor-alpha (TNF-α) and/or CD40-ligand (CD40-L).

End point type	Secondary
----------------	-----------

End point timeframe:

Twelve Months post each dose (M12)

Notes:

[39] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting values for the SB692342 2 dose Group, the SB692342 1 dose Group and the Control Menjugate Group from the baseline period.

End point values	SB692342 2 dose Group	SB692392 2 dose + Tritanrix + Prevnar + Polio Sabin Group	SB692342 1 dose Group	SB692392 1 dose + Tritanrix + Prevnar + Polio Sabin Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	38	41	45	41
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD4 all doubles, M12	456.5 (237 to 1062)	403 (245 to 745)	104 (59 to 201)	98 (52 to 157)
CD4.CD40-L(+)+IL-2(+)+TNF-α(+)+INF-γ (+), M12	51 (18 to 145)	65 (18 to 99)	16 (1 to 42)	14 (1 to 48)
CD4.CD40-L(+)+IL-2(+)+TNF-α(+)+INF-γ (-), M12	176 (73 to 424)	144 (80 to 329)	28 (12 to 52)	26 (13 to 47)
CD4.CD40-L(+)+IL-2(+)+TNF-α (-)+INF-γ (+), M12	7 (1 to 39)	13 (1 to 40)	1 (1 to 1)	1 (1 to 1)
CD4.CD40-L(+)+IL-2(+)+TNF-α (-)+INF-γ (-), M12	56.5 (24 to 145)	67 (24 to 149)	13 (1 to 21)	1 (1 to 16)
CD4.CD40-L(+)+IL-2(-)+TNF-α(+)+INF-γ (+), M12	1 (1 to 13)	1 (1 to 13)	1 (1 to 1)	1 (1 to 1)
CD4.CD40-L(+)+IL-2(-)+TNF-α(+)+INF-γ (-), M12	12.5 (1 to 37)	1 (1 to 23)	1 (1 to 1)	1 (1 to 13)
CD4.CD40-L(+)+IL-2(-)+TNF-α (-)+INF-γ (+), M12	1 (1 to 12)	1 (1 to 17)	1 (1 to 13)	1 (1 to 1)
CD4.CD40-L(+)+IL-2(-)+TNF-α (-)+INF-γ (-), M12	10.5 (1 to 57)	29 (1 to 81)	1 (1 to 48)	14 (1 to 67)
CD4.CD40-L(-)+IL-2(+)+TNF-α(+)+INF-γ (+), M12	13 (1 to 29)	1 (1 to 17)	1 (1 to 16)	1 (1 to 1)
CD4.CD40-L(-)+IL-2(+)+TNF-α(+)+INF-γ (-), M12	60 (15 to 138)	39 (13 to 91)	12 (1 to 21)	1 (1 to 12)
CD4.CD40-L(-)+IL-2(+)+TNF-α (-)+INF-γ (+), M12	21 (1 to 56)	19 (1 to 40)	1 (1 to 12)	1 (1 to 12)
CD4.CD40-L(-)+IL-2(+)+TNF-α (-)+INF-γ (-), M12	179 (84 to 283)	155 (74 to 300)	30 (1 to 66)	50 (22 to 87)
CD4.CD40-L(-)+IL-2(-)+TNF-α (+)+INF-γ(+), M12	1 (1 to 15)	1 (1 to 12)	1 (1 to 1)	1 (1 to 1)
CD4.CD40-L(-)+IL-2(-)+TNF-α (+)+INF-γ (-), M12	3.5 (1 to 38)	1 (1 to 35)	3 (1 to 40)	1 (1 to 39)

CD4.CD40-L(-)+IL-2(-)+TNF-α (-)+INF-γ(+), M12	14.5 (1 to 49)	2 (1 to 54)	1 (1 to 25)	1 (1 to 25)
---	----------------	-------------	-------------	-------------

End point values	Control Menjugate Group	Control Tritanrix + Prevnar + Polio Sabin Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	33	43		
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD4 all doubles, M12	38 (22 to 61)	41 (22 to 79)		
CD4.CD40-L(+)+IL-2(+)+TNF-α(+)+INF-γ (+), M12	1 (1 to 1)	1 (1 to 14)		
CD4.CD40-L(+)+IL-2(+)+TNF-α(+)+INF-γ (-), M12	1 (1 to 14)	1 (1 to 12)		
CD4.CD40-L(+)+IL-2(+)+TNF-α (-)+INF-γ (+), M12	1 (1 to 1)	1 (1 to 1)		
CD4.CD40-L(+)+IL-2(+)+TNF-α (-)+INF-γ (-), M12	1 (1 to 1)	1 (1 to 1)		
CD4.CD40-L(+)+IL-2(-)+TNF-α(+)+INF-γ (+), M12	1 (1 to 1)	1 (1 to 1)		
CD4.CD40-L(+)+IL-2(-)+TNF-α(+)+INF-γ (-), M12	1 (1 to 1)	1 (1 to 12)		
CD4.CD40-L(+)+IL-2(-)+TNF-α (-)+INF-γ (+), M12	1 (1 to 12)	1 (1 to 13)		
CD4.CD40-L(+)+IL-2(-)+TNF-α (-)+INF-γ (-), M12	22 (1 to 58)	13 (1 to 72)		
CD4.CD40-L(-)+IL-2(+)+TNF-α(+)+INF-γ (+), M12	1 (1 to 1)	1 (1 to 1)		
CD4.CD40-L(-)+IL-2(+)+TNF-α(+)+INF-γ (-), M12	1 (1 to 1)	1 (1 to 1)		
CD4.CD40-L(-)+IL-2(+)+TNF-α (-)+INF-γ (+), M12	1 (1 to 1)	1 (1 to 1)		
CD4.CD40-L(-)+IL-2(+)+TNF-α (-)+INF-γ (-), M12	1 (1 to 20)	3 (1 to 25)		
CD4.CD40-L(-)+IL-2(-)+TNF-α (+)+INF-γ(+), M12	1 (1 to 1)	1 (1 to 1)		
CD4.CD40-L(-)+IL-2(-)+TNF-α (+)+INF-γ (-), M12	1 (1 to 27)	1 (1 to 19)		
CD4.CD40-L(-)+IL-2(-)+TNF-α (-)+INF-γ(+), M12	1 (1 to 27)	1 (1 to 41)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Frequency of M. tuberculosis fusion protein M72 (M72)-specific cluster of differentiation (CD)8+ T cells per million cells expressing at least two different immune markers

End point title	Frequency of M. tuberculosis fusion protein M72 (M72)-specific cluster of differentiation (CD)8+ T cells per million cells expressing at least two different immune markers <sup>[40]</sup>
-----------------	---

End point description:

Immune markers expressed were among Interleukin-2 (IL-2) and/or Interferon-gamma (INF-γ) and/or Tumour necrosis factor-alpha (TNF-α) and/or CD40-ligand (CD40-L).

End point type Secondary

End point timeframe:

Before vaccination (PRE)

Notes:

[40] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting values for the SB692342 2 dose Group, the SB692342 1 dose Group and the Control Menjugate Group from the baseline period.

End point values	SB692342 2 dose Group	SB692392 2 dose + Tritanrix + Prevnar + Polio Sabin Group	SB692342 1 dose Group	SB692392 1 dose + Tritanrix + Prevnar + Polio Sabin Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	37	36	42	39
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD8 all doubles, PRE	11 (11 to 81)	40.5 (11 to 70.5)	11 (11 to 61)	11 (11 to 93)
CD8.CD40-L(+)+IL-2(+)+TNF-α(+)+INF-γ (+), PRE	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(+)+IL-2(+)+TNF-α(+)+INF-γ (-),PRE	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(+)+IL-2(+)+TNF-α (-)+INF-γ (+),PRE	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(+)+IL-2(+)+TNF-α (-)+INF-γ (-),PRE	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(+)+IL-2(-)+TNF-α(+)+INF-γ (+),PRE	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(+)+IL-2(-)+TNF-α(+)+INF-γ (-),PRE	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(+)+IL-2(-)+TNF-α (-)+INF-γ (+),PRE	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(+)+IL-2(-)+TNF-α (-)+INF-γ (-),PRE	1 (1 to 44)	1 (1 to 42)	1 (1 to 53)	1 (1 to 46)
CD8.CD40-L(-)+IL-2(+)+TNF-α(+)+INF-γ (+),PRE	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(-)+IL-2(+)+TNF-α(+)+INF-γ (-),PRE	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(-)+IL-2(+)+TNF-α (-)+INF-γ (+),PRE	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(-)+IL-2(+)+TNF-α (-)+INF-γ (-),PRE	8 (1 to 116)	117 (40 to 260)	57 (1 to 138)	61 (1 to 166)
CD8.CD40-L(-)+IL-2(-)+TNF-α (+)+INF-γ(+),PRE	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(-)+IL-2(-)+TNF-α (+)+INF-γ (-),PRE	1 (1 to 64)	1 (1 to 14.5)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(-)+IL-2(-)+TNF-α (-)+INF-γ(+),PRE	1 (1 to 40)	1 (1 to 1)	1 (1 to 23)	1 (1 to 1)

End point values	Control Menjugate	Control Tritanrix +		
------------------	-------------------	---------------------	--	--

	Group	Prevnar + Polio Sabin Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	34	39		
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD8 all doubles, PRE	11 (11 to 65)	11 (11 to 47)		
CD8.CD40-L(+)+IL-2(+)+TNF- α(+)+INF-γ (+), PRE	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(+)+IL-2(+)+TNF- α(+)+INF-γ (-),PRE	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(+)+IL-2(+)+TNF-α (- ) +INF-γ (+),PRE	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(+)+IL-2(+)+TNF-α (-)+I NF-γ (-),PRE	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(+)+IL-2(-)+TNF- α(+)+INF-γ (+),PRE	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(+)+IL-2(-)+TNF- α(+)+INF-γ (-),PRE	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(+)+IL-2(-)+TNF-α (- ) +INF-γ (+),PRE	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(+)+IL-2(-)+TNF-α (- ) +INF-γ (-),PRE	1 (1 to 50)	1 (1 to 55)		
CD8.CD40-L(-)+IL-2(+)+TNF- α(+)+INF-γ (+),PRE	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(-)+IL-2(+)+TNF- α(+)+INF-γ (-),PRE	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(-)+IL-2(+)+TNF-α (- ) +INF-γ (+),PRE	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(-)+IL-2(+)+TNF-α (- ) +INF-γ (-),PRE	53.5 (1 to 91)	65 (1 to 302)		
CD8.CD40-L(-)+IL-2(-)+TNF-α (+)+INF-γ(+),PRE	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(-)+IL-2(-)+TNF-α (+)+INF-γ (-),PRE	1 (1 to 28)	1 (1 to 27)		
CD8.CD40-L(-)+IL-2(-)+TNF-α (-)+INF- γ(+),PRE	1 (1 to 2)	1 (1 to 43)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Frequency of M. tuberculosis fusion protein M72 (M72)-specific cluster of differentiation (CD)8+ T cells per million cells expressing at least two different immune markers

End point title	Frequency of M. tuberculosis fusion protein M72 (M72)-specific cluster of differentiation (CD)8+ T cells per million cells expressing at least two different immune markers <sup>[41]</sup>
-----------------	---

End point description:

Immune markers expressed were among Interleukin-2 (IL-2) and/or Interferon-gamma (INF-γ) and/or Tumour necrosis factor-alpha (TNF-α) and/or CD40-ligand (CD40-L).

End point type	Secondary
----------------	-----------

End point timeframe:

Seven Days after each dose (D7)

Notes:

[41] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting values for the SB692342 2 dose Group, the SB692342 1 dose Group and the Control Menjugate Group from the baseline period.

End point values	SB692342 2 dose Group	SB692392 2 dose + Tritanrix + Pevnar + Polio Sabin Group	SB692342 1 dose Group	SB692392 1 dose + Tritanrix + Pevnar + Polio Sabin Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	37	42	43	43
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD8 all doubles, D7	61 (11 to 147)	55 (11 to 161)	43 (11 to 101)	46 (11 to 82)
CD8.CD40-L(+)+IL-2(+)+TNF- $\alpha$ (+)+INF- $\gamma$ (+), D7	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(+)+IL-2(+)+TNF- $\alpha$ (+)+INF- $\gamma$ (-),D7	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(+)+IL-2(+)+TNF- $\alpha$ (-)+INF- $\gamma$ (+),D7	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(+)+IL-2(+)+TNF- $\alpha$ (-)+INF- $\gamma$ (-),D7	1 (1 to 1)	1 (1 to 31)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(+)+IL-2(-)+TNF- $\alpha$ (+)+INF- $\gamma$ (+),D7	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(+)+IL-2(-)+TNF- $\alpha$ (+)+INF- $\gamma$ (-),D7	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(+)+IL-2(-)+TNF- $\alpha$ (-)+INF- $\gamma$ (+),D7	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(+)+IL-2(-)+TNF- $\alpha$ (-)+INF- $\gamma$ (-),D7	34 (1 to 104)	37 (1 to 119)	6 (1 to 116)	1 (1 to 100)
CD8.CD40-L(-)+IL-2(+)+TNF- $\alpha$ (+)+INF- $\gamma$ (+),D7	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(-)+IL-2(+)+TNF- $\alpha$ (+)+INF- $\gamma$ (-),D7	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(-)+IL-2(+)+TNF- $\alpha$ (-)+INF- $\gamma$ (+),D7	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(-)+IL-2(+)+TNF- $\alpha$ (-)+INF- $\gamma$ (-),D7	61 (1 to 185)	161.5 (1 to 574)	1 (1 to 107)	34 (1 to 303)
CD8.CD40-L(-)+IL-2(-)+TNF- $\alpha$ (+)+INF- $\gamma$ (+),D7	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(-)+IL-2(-)+TNF- $\alpha$ (+)+INF- $\gamma$ (-),D7	6 (1 to 64)	7.5 (1 to 72)	1 (1 to 67)	1 (1 to 10)
CD8.CD40-L(-)+IL-2(-)+TNF- $\alpha$ (-)+INF- $\gamma$ (+),D7	37 (1 to 89)	1 (1 to 50)	1 (1 to 70)	1 (1 to 31)

End point values	Control Menjugate Group	Control Tritanrix + Pevnar + Polio Sabin Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	37	44		
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD8 all doubles, D7	11 (11 to 11)	11 (11 to 28)		

CD8.CD40-L(+)+IL-2(+)+TNF- α(+)+INF-γ (+), D7	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(+)+IL-2(+)+TNF- α(+)+INF-γ (-),D7	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(+)+IL-2(+)+TNF-α (- ) +INF-γ (+),D7	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(+)+IL-2(+)+TNF-α (-)+I NF-γ (-),D7	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(+)+IL-2(-)+TNF- α(+)+INF-γ (+),D7	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(+)+IL-2(-)+TNF- α(+)+INF-γ (-),D7	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(+)+IL-2(-)+TNF-α (- ) +INF-γ (+),D7	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(+)+IL-2(-)+TNF-α (- ) +INF-γ (-),D7	3 (1 to 54)	1 (1 to 25)		
CD8.CD40-L(-)+IL-2(+)+TNF- α(+)+INF-γ (+),D7	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(-)+IL-2(+)+TNF- α(+)+INF-γ (-),D7	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(-)+IL-2(+)+TNF-α (- ) +INF-γ (+),D7	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(-)+IL-2(+)+TNF-α (- ) +INF-γ (-),D7	1 (1 to 61)	123 (1 to 289.5)		
CD8.CD40-L(-)+IL-2(-)+TNF-α (+)+INF-γ(+),D7	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(-)+IL-2(-)+TNF-α (+)+INF-γ (-),D7	1 (1 to 85)	1 (1 to 48)		
CD8.CD40-L(-)+IL-2(-)+TNF-α (-)+INF- γ(+),D7	1 (1 to 30)	1 (1 to 2.5)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Frequency of M. tuberculosis fusion protein M72 (M72)-specific cluster of differentiation (CD)8+ T cells per million cells expressing at least two different immune markers

End point title	Frequency of M. tuberculosis fusion protein M72 (M72)-specific cluster of differentiation (CD)8+ T cells per million cells expressing at least two different immune markers <sup>[42]</sup>
-----------------	---

End point description:

Immune markers expressed were among Interleukin-2 (IL-2) and/or Interferon-gamma (INF-γ) and/or Tumour necrosis factor-alpha (TNF-α) and/or CD40-ligand (CD40-L).

End point type	Secondary
----------------	-----------

End point timeframe:

One Month after each dose (M1)

Notes:

[42] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting values for the SB692342 2 dose Group, the SB692342 1 dose Group and the Control Menjugate Group from the baseline period.

End point values	SB692342 2 dose Group	SB692392 2 dose + Tritanrix + Pevnar + Polio Sabin Group	SB692342 1 dose Group	SB692392 1 dose + Tritanrix + Pevnar + Polio Sabin Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	41	43	44	41
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD8 all doubles, M1	69 (11 to 145)	82 (11 to 163)	29.5 (11 to 80)	81 (26 to 139)
CD8.CD40-L(+)+IL-2(+)+TNF- $\alpha$ (+)+INF- $\gamma$ (+), M1	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(+)+IL-2(+)+TNF- $\alpha$ (+)+INF- $\gamma$ (-),M1	1 (1 to 1)	1 (1 to 32)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(+)+IL-2(+)+TNF- $\alpha$ (-)+INF- $\gamma$ (+),M1	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(+)+IL-2(+)+TNF- $\alpha$ (-)+INF- $\gamma$ (-),M1	1 (1 to 1)	1 (1 to 32)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(+)+IL-2(-)+TNF- $\alpha$ (+)+INF- $\gamma$ (+),M1	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(+)+IL-2(-)+TNF- $\alpha$ (+)+INF- $\gamma$ (-),M1	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(+)+IL-2(-)+TNF- $\alpha$ (-)+INF- $\gamma$ (+),M1	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 56)
CD8.CD40-L(+)+IL-2(-)+TNF- $\alpha$ (-)+INF- $\gamma$ (-),M1	1 (1 to 55)	1 (1 to 46)	1 (1 to 52)	11 (1 to 99)
CD8.CD40-L(-)+IL-2(+)+TNF- $\alpha$ (+)+INF- $\gamma$ (+),M1	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(-)+IL-2(+)+TNF- $\alpha$ (+)+INF- $\gamma$ (-),M1	1 (1 to 12)	1 (1 to 28)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(-)+IL-2(+)+TNF- $\alpha$ (-)+INF- $\gamma$ (+),M1	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(-)+IL-2(+)+TNF- $\alpha$ (-)+INF- $\gamma$ (-),M1	1 (1 to 139)	142 (1 to 308)	2.5 (1 to 116)	109 (2 to 218)
CD8.CD40-L(-)+IL-2(-)+TNF- $\alpha$ (+)+INF- $\gamma$ (+),M1	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(-)+IL-2(-)+TNF- $\alpha$ (+)+INF- $\gamma$ (-),M1	18 (1 to 87)	12 (1 to 111)	1 (1 to 50)	1 (1 to 90)
CD8.CD40-L(-)+IL-2(-)+TNF- $\alpha$ (-)+INF- $\gamma$ (+),M1	1 (1 to 65)	1 (1 to 65)	1 (1 to 5.5)	1 (1 to 64)

End point values	Control Menjugate Group	Control Tritanrix + Pevnar + Polio Sabin Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	34	42		
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD8 all doubles, M1	11 (11 to 28)	11 (11 to 53)		
CD8.CD40-L(+)+IL-2(+)+TNF- $\alpha$ (+)+INF- $\gamma$ (+), M1	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(+)+IL-2(+)+TNF- $\alpha$ (+)+INF- $\gamma$ (-),M1	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(+)+IL-2(+)+TNF- $\alpha$ (-)+INF- $\gamma$ (+),M1	1 (1 to 1)	1 (1 to 1)		

CD8.CD40-L(+)+IL-2(+)+TNF-α (-)+I INF-γ (-),M1	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(+)+IL-2(-)+TNF- α(+)+INF-γ (+),M1	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(+)+IL-2(-)+TNF- α(+)+INF-γ (-),M1	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(+)+IL-2(-)+TNF-α (- ) +INF-γ (+),M1	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(+)+IL-2(-)+TNF-α (- ) +INF-γ (-),M1	2.5 (1 to 85)	4 (1 to 109)		
CD8.CD40-L(-)+IL-2(+)+TNF- α(+)+INF-γ (+),M1	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(-)+IL-2(+)+TNF- α(+)+INF-γ (-),M1	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(-)+IL-2(+)+TNF-α (- ) +INF-γ (+),M1	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(-)+IL-2(+)+TNF-α (- ) +INF-γ (-),M1	1 (1 to 48)	86 (1 to 330)		
CD8.CD40-L(-)+IL-2(-)+TNF-α (+) +INF-γ(+),M1	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(-)+IL-2(-)+TNF-α (+) +INF-γ (-),M1	1 (1 to 51)	1 (1 to 35)		
CD8.CD40-L(-)+IL-2(-)+TNF-α (-)+INF- γ(+),M1	1 (1 to 5)	1 (1 to 1)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Frequency of M. tuberculosis fusion protein M72 (M72)-specific cluster of differentiation (CD)8+ T cells per million cells expressing at least two different immune markers

End point title	Frequency of M. tuberculosis fusion protein M72 (M72)-specific cluster of differentiation (CD)8+ T cells per million cells expressing at least two different immune markers <sup>[43]</sup>
-----------------	---

End point description:

Immune markers expressed were among Interleukin-2 (IL-2) and/or Interferon-gamma (INF-γ) and/or Tumour necrosis factor-alpha (TNF-α) and/or CD40-ligand (CD40-L).

End point type	Secondary
----------------	-----------

End point timeframe:

Six Months after each dose (M6)

Notes:

[43] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting values for the SB692342 2 dose Group, the SB692342 1 dose Group and the Control Menjugate Group from the baseline period.

End point values	SB692342 2 dose Group	SB692392 2 dose + Tritanrix + Pevnar + Polio Sabin Group	SB692342 1 dose Group	SB692392 1 dose + Tritanrix + Pevnar + Polio Sabin Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	36	40	42	43
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				



CD8 all doubles, M6	11 (11 to 53)	11 (11 to 20)	11 (11 to 32)	11 (11 to 11)
CD8.CD40-L(+)+IL-2(+)+TNF- α(+)+INF-γ (+), M6	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(+)+IL-2(+)+TNF- α(+)+INF-γ (-),M6	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(+)+IL-2(+)+TNF-α (- ) +INF-γ (+),M6	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(+)+IL-2(+)+TNF-α (-)+I INF-γ (-),M6	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(+)+IL-2(-)+TNF- α(+)+INF-γ (+),M6	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(+)+IL-2(-)+TNF- α(+)+INF-γ (-),M6	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(+)+IL-2(-)+TNF-α (- ) +INF-γ (+),M6	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(+)+IL-2(-)+TNF-α (- ) +INF-γ (-),M6	1 (1 to 25.5)	2 (1 to 65)	1 (1 to 44)	1 (1 to 63)
CD8.CD40-L(-)+IL-2(+)+TNF- α(+)+INF-γ (+),M6	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(-)+IL-2(+)+TNF- α(+)+INF-γ (-),M6	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(-)+IL-2(+)+TNF-α (- ) +INF-γ (+),M6	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(-)+IL-2(+)+TNF-α (- ) +INF-γ (-),M6	1 (1 to 29.5)	27.5 (1 to 60)	38 (1 to 91)	1 (1 to 56)
CD8.CD40-L(-)+IL-2(-)+TNF-α (+)+INF-γ(+),M6	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(-)+IL-2(-)+TNF-α (+)+INF-γ (-),M6	1 (1 to 54.5)	1 (1 to 55.5)	1 (1 to 3)	1 (1 to 60)
CD8.CD40-L(-)+IL-2(-)+TNF-α (-)+INF- γ(+),M6	1 (1 to 33)	1 (1 to 36.5)	1 (1 to 1)	1 (1 to 40)

<b>End point values</b>	Control Menjugate Group	Control Tritanrix + Prevnar + Polio Sabin Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	34	44		
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD8 all doubles, M6	11 (11 to 29)	11 (11 to 11)		
CD8.CD40-L(+)+IL-2(+)+TNF- α(+)+INF-γ (+), M6	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(+)+IL-2(+)+TNF- α(+)+INF-γ (-),M6	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(+)+IL-2(+)+TNF-α (- ) +INF-γ (+),M6	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(+)+IL-2(+)+TNF-α (-)+I INF-γ (-),M6	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(+)+IL-2(-)+TNF- α(+)+INF-γ (+),M6	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(+)+IL-2(-)+TNF- α(+)+INF-γ (-),M6	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(+)+IL-2(-)+TNF-α (- ) +INF-γ (+),M6	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(+)+IL-2(-)+TNF-α (- ) +INF-γ (-),M6	1 (1 to 52)	2 (1 to 59)		

CD8.CD40-L(-)+IL-2(+)+TNF- α(+)+INF-γ (+),M6	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(-)+IL-2(+)+TNF- α(+)+INF-γ (-),M6	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(-)+IL-2(+)+TNF-α (- ) +INF-γ (+),M6	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(-)+IL-2(+)+TNF-α (- ) +INF-γ (-),M6	28 (1 to 67)	1 (1 to 43.5)		
CD8.CD40-L(-)+IL-2(-)+TNF-α (+)+INF-γ(+),M6	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(-)+IL-2(-)+TNF-α (+)+INF-γ (-),M6	1 (1 to 36)	1 (1 to 49)		
CD8.CD40-L(-)+IL-2(-)+TNF-α (-)+INF- γ(+),M6	1 (1 to 1)	1 (1 to 1)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Frequency of M. tuberculosis fusion protein M72 (M72)-specific cluster of differentiation (CD)8+ T cells per million cells expressing at least two different immune markers

End point title	Frequency of M. tuberculosis fusion protein M72 (M72)-specific cluster of differentiation (CD)8+ T cells per million cells expressing at least two different immune markers <sup>[44]</sup>
-----------------	---

End point description:

Immune markers expressed were among Interleukin-2 (IL-2) and/or Interferon-gamma (INF-γ) and/or Tumour necrosis factor-alpha (TNF-α) and/or CD40-ligand (CD40-L).

End point type	Secondary
----------------	-----------

End point timeframe:

Twelve Months after each dose (M12)

Notes:

[44] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting values for the SB692342 2 dose Group, the SB692342 1 dose Group and the Control Menjugate Group from the baseline period.

End point values	SB692342 2 dose Group	SB692392 2 dose + Tritanrix + Pevnar + Polio Sabin Group	SB692342 1 dose Group	SB692392 1 dose + Tritanrix + Pevnar + Polio Sabin Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	38	41	45	41
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD8 all doubles, M12	11 (11 to 52)	11 (11 to 35)	11 (11 to 38)	11 (11 to 41)
CD8.CD40-L(+)+IL-2(+)+TNF- α(+)+INF-γ (+), M12	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(+)+IL-2(+)+TNF- α(+)+INF-γ (-),M12	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(+)+IL-2(+)+TNF-α (- ) +INF-γ (+),M12	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(+)+IL-2(+)+TNF-α (-)+I INF-γ (-),M12	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)

CD8.CD40-L(+)+IL-2(-)+TNF- α(+)+INF-γ (+),M12	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(+)+IL-2(-)+TNF- α(+)+INF-γ (-),M12	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(+)+IL-2(-)+TNF-α (- ) +INF-γ (+),M12	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(+)+IL-2(-)+TNF-α (- ) +INF-γ (-),M12	1 (1 to 29)	1 (1 to 64)	1 (1 to 68)	1 (1 to 35)
CD8.CD40-L(-)+IL-2(+)+TNF- α(+)+INF-γ (+),M12	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(-)+IL-2(+)+TNF- α(+)+INF-γ (-),M12	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(-)+IL-2(+)+TNF-α (- ) +INF-γ (+),M12	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(-)+IL-2(+)+TNF-α (- ) +INF-γ (-),M12	14.5 (1 to 92)	16 (1 to 77)	1 (1 to 59)	1 (1 to 35)
CD8.CD40-L(-)+IL-2(-)+TNF-α (+) +INF-γ(+),M12	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)	1 (1 to 1)
CD8.CD40-L(-)+IL-2(-)+TNF-α (+) +INF-γ (-),M12	1 (1 to 34)	1 (1 to 50)	1 (1 to 58)	1 (1 to 65)
CD8.CD40-L(-)+IL-2(-)+TNF-α (-)+INF- γ(+),M12	1.5 (1 to 67)	1 (1 to 48)	1 (1 to 25)	1 (1 to 128)

<b>End point values</b>	Control Menjugate Group	Control Tritanrix + Prevnar + Polio Sabin Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	33	43		
Units: T cells/million cells				
median (inter-quartile range (Q1-Q3))				
CD8 all doubles, M12	11 (11 to 41)	11 (11 to 42)		
CD8.CD40-L(+)+IL-2(+)+TNF- α(+)+INF-γ (+), M12	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(+)+IL-2(+)+TNF- α(+)+INF-γ (-),M12	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(+)+IL-2(+)+TNF-α (- ) +INF-γ (+),M12	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(+)+IL-2(+)+TNF-α (-)+I INF-γ (-),M12	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(+)+IL-2(-)+TNF- α(+)+INF-γ (+),M12	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(+)+IL-2(-)+TNF- α(+)+INF-γ (-),M12	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(+)+IL-2(-)+TNF-α (- ) +INF-γ (+),M12	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(+)+IL-2(-)+TNF-α (- ) +INF-γ (-),M12	1 (1 to 32)	1 (1 to 40)		
CD8.CD40-L(-)+IL-2(+)+TNF- α(+)+INF-γ (+),M12	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(-)+IL-2(+)+TNF- α(+)+INF-γ (-),M12	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(-)+IL-2(+)+TNF-α (- ) +INF-γ (+),M12	1 (1 to 1)	1 (1 to 1)		
CD8.CD40-L(-)+IL-2(+)+TNF-α (- ) +INF-γ (-),M12	1 (1 to 57)	15 (1 to 66)		
CD8.CD40-L(-)+IL-2(-)+TNF-α (+) +INF-γ(+),M12	1 (1 to 5)	1 (1 to 1)		

CD8.CD40-L(-)+IL-2(-)+TNF-α (+)+INF-γ (-),M12	1 (1 to 117)	1 (1 to 22)		
CD8.CD40-L(-)+IL-2(-)+TNF-α (-)+INF-γ(+),M12	11 (1 to 57)	1 (1 to 33)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of seropositive subjects against M72 antigen

End point title	Number of seropositive subjects against M72 antigen <sup>[45]</sup>
End point description: A seropositive subject was a subject whose M72 antibody concentration was greater than or equal to 2.8 ELISA units per millilitre (EL.U/mL).	
End point type	Secondary
End point timeframe: Before vaccination (PRE) and after each dose [at 1, 6 and 12 months post-vaccination (M1, M6 and M12)]	

Notes:

[45] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting values for the SB692342 2 dose Group, the SB692342 1 dose Group and the Control Menjugate Group from the baseline period.

End point values	SB692342 2 dose Group	SB692392 2 dose + Tritanrix + Pevnar + Polio Sabin Group	SB692342 1 dose Group	SB692392 1 dose + Tritanrix + Pevnar + Polio Sabin Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	43	44	48	46
Units: Subjects				
Anti-M72, PRE (N=43;44;48;46;39;46)	0	0	0	0
Anti-M72, M1 (N=42;43;45;44;34;43)	42	43	39	39
Anti-M72, M6 (N=40;41;45;45;36;45)	40	41	32	35
Anti-M72, M12 (N=41;42;47;45;35;43)	41	42	35	31

End point values	Control Menjugate Group	Control Tritanrix + Pevnar + Polio Sabin Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	39	46		
Units: Subjects				
Anti-M72, PRE (N=43;44;48;46;39;46)	1	0		
Anti-M72, M1 (N=42;43;45;44;34;43)	1	0		
Anti-M72, M6 (N=40;41;45;45;36;45)	0	1		
Anti-M72, M12 (N=41;42;47;45;35;43)	1	2		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Concentration of antibodies against M72 antigen

End point title	Concentration of antibodies against M72 antigen <sup>[46]</sup>
-----------------	---

End point description:

Concentrations given in EL.U/mL were expressed as Geometric Mean Concentrations (GMCs).

End point type	Secondary
----------------	-----------

End point timeframe:

Before vaccination (PRE) and after each dose [at 1, 6 and 12 months post-vaccination (M1, M6 and M12)]

Notes:

[46] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting values for the SB692342 2 dose Group, the SB692342 1 dose Group and the Control Menjugate Group from the baseline period.

End point values	SB692342 2 dose Group	SB692392 2 dose + Tritanrix + Prevnar + Polio Sabin Group	SB692342 1 dose Group	SB692392 1 dose + Tritanrix + Prevnar + Polio Sabin Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	43	44	48	46
Units: EL.U/mL				
geometric mean (confidence interval 95%)				
Anti-M72, PRE (N=43;44;48;46;39;46)	1.4 (1.4 to 1.4)	1.4 (1.4 to 1.4)	1.4 (1.4 to 1.4)	1.4 (1.4 to 1.4)
Anti-M72, M1 (N=42;43;45;44;34;43)	1275.2 (981.3 to 1657.2)	1264 (928 to 1721.5)	8 (6 to 10.7)	7.4 (5.3 to 10.2)
Anti-M72, M6 (N=40;41;45;45;36;45)	98.9 (75.2 to 130.1)	102.6 (78.7 to 133.9)	4.6 (3.4 to 6.2)	4.9 (3.8 to 6.4)
Anti-M72, M12 (N=41;42;47;45;35;43)	68.3 (50.7 to 92)	76 (56.6 to 102)	5.3 (3.9 to 7)	4.3 (3.2 to 5.8)

End point values	Control Menjugate Group	Control Tritanrix + Prevnar + Polio Sabin Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	39	46		
Units: EL.U/mL				
geometric mean (confidence interval				

95%)				
Anti-M72, PRE (N=43;44;48;46;39;46)	1.5 (1.3 to 1.7)	1.4 (1.4 to 1.4)		
Anti-M72, M1 (N=42;43;45;44;34;43)	1.5 (1.3 to 1.7)	1.4 (1.4 to 1.4)		
Anti-M72, M6 (N=40;41;45;45;36;45)	1.4 (1.4 to 1.4)	1.4 (1.4 to 1.5)		
Anti-M72, M12 (N=41;42;47;45;35;43)	1.4 (1.4 to 1.5)	1.5 (1.4 to 1.7)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of seroprotected subjects against diphtheria toxoid (Anti-D) and tetanus toxoid (Anti-T)

End point title	Number of seroprotected subjects against diphtheria toxoid (Anti-D) and tetanus toxoid (Anti-T)
-----------------	---

End point description:

A seroprotected subject was a subject whose anti-diphtheria toxoid (anti-D)/anti-tetanus toxoid (anti-T) antibody concentration was greater than or equal to ( $\geq$ ) 0.1 international-units per millilitre (IU/mL).

End point type	Secondary
----------------	-----------

End point timeframe:

Before vaccination (PRE) and 1 Month post Dose 3 [PIII(M3)]

End point values	SB692392 2 dose + Tritanrix + Prevnar + Polio Sabin Group	SB692392 1 dose + Tritanrix + Prevnar + Polio Sabin Group	Control Tritanrix + Prevnar + Polio Sabin Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	43	43	43	
Units: Subjects				
Anti-D, PRE (N=37,38,38)	6	10	6	
Anti-D,PIII(M3) (N=43,43,43)	43	43	43	
Anti-T, PRE(N=37,38,38)	32	35	35	
Anti-T,PIII(M3) (N=43,43,43)	43	43	43	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Anti-D, Anti-T antibody concentrations

End point title	Anti-D, Anti-T antibody concentrations
-----------------	--

End point description:

Concentrations given in IU/mL, were expressed as Geometric Mean Concentrations (GMCs).

End point type	Secondary
----------------	-----------

End point timeframe:

Before vaccination (PRE) and 1 Month post Dose 3 [PIII(M3)]

End point values	SB692392 2 dose + Tritanrix + Pevnar + Polio Sabin Group	SB692392 1 dose + Tritanrix + Pevnar + Polio Sabin Group	Control Tritanrix + Pevnar + Polio Sabin Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	43	43	43	
Units: IU/mL				
geometric mean (confidence interval 95%)				
Anti-D, PRE (N=37,38,38)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	
Anti-D,PIII(M3) (N=43,43,43)	2.1 (1.6 to 2.7)	2.4 (1.8 to 3.1)	2.5 (2 to 3.1)	
Anti-T, PRE(N=37,38,38)	0.6 (0.4 to 1)	1 (0.6 to 1.5)	1 (0.6 to 1.6)	
Anti-T,PIII(M3) (N=43,43,43)	5.5 (4.3 to 7.1)	4.8 (3.6 to 6.4)	6.3 (4.8 to 8.3)	

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of seroprotected subjects against Haemophilus influenza Type B (Anti-PRP)

End point title	Number of seroprotected subjects against Haemophilus influenza Type B (Anti-PRP)
-----------------	--

End point description:

A seroprotected subject was a subject whose anti-PRP antibody concentration was  $\geq 0.15$  micrograms per millilitre ( $\mu\text{g/mL}$ ).

End point type	Secondary
----------------	-----------

End point timeframe:

Before vaccination (PRE) and 1 Month post Dose 3 [PIII(M3)]

End point values	SB692392 2 dose + Tritanrix + Pevnar + Polio Sabin Group	SB692392 1 dose + Tritanrix + Pevnar + Polio Sabin Group	Control Tritanrix + Pevnar + Polio Sabin Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	47	46	48	
Units: Subjects				
Anti-PRP, PRE (N=47,46,48)	8	14	12	
Anti-PRP,PIII(M3) (N=44,44,43)	44	44	43	

## Statistical analyses

No statistical analyses for this end point

### Secondary: Anti-PRP antibody concentrations

End point title Anti-PRP antibody concentrations

End point description:

Concentrations given in µg/mL were expressed as Geometric Mean Concentrations (GMCs).

End point type Secondary

End point timeframe:

Before vaccination (PRE) and 1 Month post Dose 3 [PIII(M3)]

End point values	SB692392 2 dose + Tritanrix + Pevnar + Polio Sabin Group	SB692392 1 dose + Tritanrix + Pevnar + Polio Sabin Group	Control Tritanrix + Pevnar + Polio Sabin Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	47	46	48	
Units: µg/mL				
geometric mean (confidence interval 95%)				
Anti-PRP, PRE (N=47,46,48)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.2)	0.1 (0.1 to 0.2)	
Anti-PRP,PIII(M3) (N=44,44,43)	28.2 (20.3 to 39.1)	30.3 (21.8 to 42.1)	31.2 (21.8 to 44.7)	

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of seropositive subjects against Bordetella Pertussis (Anti-BPT)

End point title Number of seropositive subjects against Bordetella Pertussis (Anti-BPT)

End point description:

A seropositive subject was a subject whose anti-BPT antibody concentration was  $\geq 15$  EL.U/mL.

End point type Secondary

End point timeframe:

Before vaccination (PRE) and 1 Month post Dose 3 [PIII(M3)]



End point values	SB692392 2 dose + Tritanrix + Prevnar + Polio Sabin Group	SB692392 1 dose + Tritanrix + Prevnar + Polio Sabin Group	Control Tritanrix + Prevnar + Polio Sabin Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	44	43	43	
Units: Subjects				
Anti-BPT, PRE (N=41,40,43)	1	1	1	
Anti-BPT,PIII(M3) (N=44,43,43)	44	43	43	

### Statistical analyses

No statistical analyses for this end point

### Secondary: Anti-BPT antibody concentrations

End point title	Anti-BPT antibody concentrations
End point description: Concentrations given in EL.U/mL were expressed as Geometric Mean Concentrations (GMCs).	
End point type	Secondary
End point timeframe: Before vaccination (PRE) and 1 Month post Dose 3 [PIII(M3)]	

End point values	SB692392 2 dose + Tritanrix + Prevnar + Polio Sabin Group	SB692392 1 dose + Tritanrix + Prevnar + Polio Sabin Group	Control Tritanrix + Prevnar + Polio Sabin Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	44	43	43	
Units: EL.U/mL				
geometric mean (confidence interval 95%)				
Anti-BPT, PRE (N=41,40,43)	7.7 (7.3 to 8)	7.6 (7.4 to 7.9)	7.6 (7.4 to 7.9)	
Anti-BPT,PIII(M3) (N=44,43,43)	139.4 (117.7 to 164.9)	132.1 (116.6 to 149.5)	131.5 (113.5 to 152.5)	

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of seropositive subjects against Hepatitis B (Anti-HB)

End point title	Number of seropositive subjects against Hepatitis B (Anti-HB)
End point description: A seropositive subject was a subject whose anti-HB antibody concentration was $\geq 10$ milli-international units per millilitre (mIU/mL).	

End point type	Secondary
End point timeframe:	
Before vaccination (PRE) and 1 Month post Dose 3 [PIII(M3)]	

End point values	SB692392 2 dose + Tritanrix + Pevnar + Polio Sabin Group	SB692392 1 dose + Tritanrix + Pevnar + Polio Sabin Group	Control Tritanrix + Pevnar + Polio Sabin Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	44	44	43	
Units: Subjects				
Anti-HB, PRE (N=41,40,41)	9	14	13	
Anti-HB, PIII(M3) (N=44,44,43)	42	43	42	

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of seropositive subjects against Hepatitis B (Anti-HB) with antibody concentrations $\geq 100$ mIU/mL

End point title	Number of seropositive subjects against Hepatitis B (Anti-HB) with antibody concentrations $\geq 100$ mIU/mL
-----------------	--

End point description:

A decrease in the specificity of the anti-HB ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU/mL). The table shows updated results following partial or complete retesting/reanalysis. Following from this, the table shows data with titers  $\geq 100$  mIU/mL.

End point type	Secondary
End point timeframe:	
Before vaccination (PRE) and 1 Month post Dose 3 [PIII(M3)]	

End point values	SB692392 2 dose + Tritanrix + Pevnar + Polio Sabin Group	SB692392 1 dose + Tritanrix + Pevnar + Polio Sabin Group	Control Tritanrix + Pevnar + Polio Sabin Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	44	44	43	
Units: Subjects				
Anti-HB, PRE (N=41,40,41)	2	2	2	
Anti-HB,PIII(M3) (N=44,44,43)	42	42	42	

## Statistical analyses

No statistical analyses for this end point

### Secondary: Anti-HB antibody concentrations

End point title	Anti-HB antibody concentrations
-----------------	---------------------------------

End point description:

Concentrations given in mIU/mL were expressed as Geometric Mean Concentrations (GMCs).

End point type	Secondary
----------------	-----------

End point timeframe:

Before vaccination (PRE) and 1 Month post Dose 3 [PIII(M3)]

End point values	SB692392 2 dose + Tritanrix + Pevnar + Polio Sabin Group	SB692392 1 dose + Tritanrix + Pevnar + Polio Sabin Group	Control Tritanrix + Pevnar + Polio Sabin Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	44	44	43	
Units: mIU/mL				
geometric mean (confidence interval 95%)				
Anti-HB, PRE (N=41,40,41)	8.3 (6 to 11.4)	10 (7.1 to 14)	9 (6.7 to 12.2)	
Anti-HB,PIII(M3) (N=44,44,43)	1725.5 (1045 to 2849)	1471.8 (947.5 to 2286)	2153 (1468.2 to 3157.4)	

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of seropositive subjects against Polio (Anti-Polio1, Anti-Polio2, Anti-Polio3)

End point title	Number of seropositive subjects against Polio (Anti-Polio1, Anti-Polio2, Anti-Polio3)
-----------------	---

End point description:

A seropositive subject was a subject whose anti-polio antibody titer was  $\geq 1:8$ .

End point type	Secondary
----------------	-----------

End point timeframe:

Before vaccination (PRE) and 1 Month post Dose 3 [PIII(M3)]

End point values	SB692392 2 dose + Tritanrix + Prevnar + Polio Sabin Group	SB692392 1 dose + Tritanrix + Prevnar + Polio Sabin Group	Control Tritanrix + Prevnar + Polio Sabin Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	46	45	48	
Units: Subjects				
Anti-Polio1, PRE (N=46,45,48)	36	38	39	
Anti-Polio1, PIII(M3) (N=44,44,43)	41	43	42	
Anti-Polio2,PRE (N=46,45,48)	33	32	38	
Anti-Polio2,PIII(M3) (N=44,44,43)	43	42	42	
Anti-Polio3,PRE (N=46,45,48)	21	18	14	
Anti-Polio3,PIII(M3) (N=44,44,43)	42	38	39	

## Statistical analyses

No statistical analyses for this end point

### Secondary: Anti-Polio1, Anti-Polio2, Anti-Polio3 antibody titers

End point title	Anti-Polio1, Anti-Polio2, Anti-Polio3 antibody titers
End point description: Concentrations given in titers were expressed as Geometric Mean Titers (GMTs).	
End point type	Secondary
End point timeframe: Before vaccination (PRE) and 1 Month post Dose 3 [PIII(M3)]	

End point values	SB692392 2 dose + Tritanrix + Prevnar + Polio Sabin Group	SB692392 1 dose + Tritanrix + Prevnar + Polio Sabin Group	Control Tritanrix + Prevnar + Polio Sabin Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	46	45	48	
Units: Titer				
geometric mean (confidence interval 95%)				
Anti-Polio1, PRE (N=46,45,48)	56.3 (30.7 to 103.2)	48.8 (27.3 to 87.5)	103.8 (58.1 to 185.3)	
Anti-Polio1, PIII(M3) (N=44,44,43)	299.9 (167.6 to 536.7)	397.8 (240.2 to 658.8)	573.1 (368.7 to 890.6)	
Anti-Polio2,PRE (N=46,45,48)	51.8 (28.8 to 93.2)	53.2 (28 to 101)	61.2 (34.8 to 107.8)	
Anti-Polio2,PIII(M3) (N=44,44,43)	458.7 (307.7 to 683.7)	524.3 (331.1 to 830.3)	499.9 (317.7 to 786.5)	
Anti-Polio3,PRE (N=46,45,48)	15.2 (9 to 25.6)	15.4 (8.6 to 27.6)	10.9 (6.7 to 17.9)	
Anti-Polio3,PIII(M3) (N=44,44,43)	154.8 (100.8 to 237.8)	103.5 (59.7 to 179.6)	123 (73.6 to 205.8)	

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of seropositive subjects against Streptococcus pneumoniae (Anti-4, Anti-6B, Anti-9V, Anti-14, Anti-18C, Anti-19F, Anti-23F)

End point title	Number of seropositive subjects against Streptococcus pneumoniae (Anti-4, Anti-6B, Anti-9V, Anti-14, Anti-18C, Anti-19F, Anti-23F)
-----------------	--

End point description:

A seropositive subject was a subject whose anti-S pneumoniae antibody concentration was  $\geq 0.05$   $\mu\text{g/mL}$ .

End point type	Secondary
----------------	-----------

End point timeframe:

Before vaccination (PRE) and 1 Month post Dose 3 [PIII(M3)]

End point values	SB692392 2 dose + Tritanrix + Prevnar + Polio Sabin Group	SB692392 1 dose + Tritanrix + Prevnar + Polio Sabin Group	Control Tritanrix + Prevnar + Polio Sabin Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	44	44	43	
Units: Subjects				
Anti-4, PRE (N=39,39,40)	18	21	12	
Anti-4, PIII(M3) (N=43,43,43)	43	43	43	
Anti-6B,PRE (N=38,39,40)	29	27	26	
Anti-6B,PIII(M3) (N=44,43,43)	44	41	40	
Anti-9V,PRE (N=37,39,39)	28	33	25	
Anti-9V,PIII(M3) (N=43,43,43)	43	43	43	
Anti-14,PRE (N=39,38,40)	39	38	38	
Anti-14,PIII(M3) (N=44,44,43)	44	44	43	
Anti-18C, PRE (N=42,40,42)	30	35	26	
Anti-18C, PIII(M3) (N=43,44,43)	43	44	43	
Anti-19F, PRE (N=37,38,40)	35	37	39	
Anti-19F, PIII(M3) (N=44,44,43)	44	44	43	
Anti-23F,PRE (N=41,40,42)	25	30	26	
Anti-23F, PIII(M3) (N=44,43,43)	43	43	42	

## Statistical analyses

No statistical analyses for this end point

**Secondary: Number of subjects with S. pneumoniae antibody concentrations  $\geq 0.2$   $\mu\text{g/mL}$**

End point title	Number of subjects with S. pneumoniae antibody concentrations $\geq 0.2$ $\mu\text{g/mL}$
-----------------	---

End point description:

A seroconverted subject is a vaccinated subject with at least a four fold increased antibody titer post vaccination.

End point type	Secondary
----------------	-----------

End point timeframe:

Before vaccination (PRE) and 1 Month post Dose 3 [PIII(M3)]

End point values	SB692392 2 dose + Tritanrix + Pevnar + Polio Sabin Group	SB692392 1 dose + Tritanrix + Pevnar + Polio Sabin Group	Control Tritanrix + Pevnar + Polio Sabin Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	44	44	43	
Units: Subjects				
Anti-4, PRE (N=39,39,40)	5	10	2	
Anti-4, PIII(M3) (N=43,43,43)	43	43	43	
Anti-6B,PRE (N=38,39,40)	8	5	6	
Anti-6B,PIII(M3) (N=44,43,43)	38	40	35	
Anti-9V,PRE (N=37,39,39)	18	20	10	
Anti-9V,PIII(M3) (N=43,43,43)	43	43	43	
Anti-14,PRE (N=39,38,40)	34	33	33	
Anti-14,PIII(M3) (N=44,44,43)	44	43	43	
Anti-18C, PRE (N=42,40,42)	10	17	9	
Anti-18C, PIII(M3) (N=43,44,43)	43	43	42	
Anti-19F, PRE (N=37,38,40)	30	30	26	
Anti-19F, PIII(M3) (N=44,44,43)	43	44	43	
Anti-23F,PRE (N=41,40,42)	9	11	14	
Anti-23F, PIII(M3) (N=44,43,43)	42	41	42	

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Anti-4, Anti-6B, Anti-9V, Anti-14, Anti-18C, Anti-19F, Anti-23F antibody concentrations**

End point title	Anti-4, Anti-6B, Anti-9V, Anti-14, Anti-18C, Anti-19F, Anti-23F antibody concentrations
-----------------	---

End point description:

Concentrations, given in  $\mu\text{g/mL}$ , were expressed as Geometric Mean Concentrations (GMCs).

End point type	Secondary
----------------	-----------

End point timeframe:

Before vaccination (PRE) and 1 Month post Dose 3 [PIII(M3)]

End point values	SB692392 2 dose + Tritanrix + Pevnar + Polio Sabin Group	SB692392 1 dose + Tritanrix + Pevnar + Polio Sabin Group	Control Tritanrix + Pevnar + Polio Sabin Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	44	44	43	
Units: µg/mL				
geometric mean (confidence interval 95%)				
Anti-4, PRE (N=39,39,40)	0.1 (0 to 0.1)	0.1 (0.1 to 0.1)	0 (0 to 0)	
Anti-4, PIII(M3) (N=43,43,43)	7.7 (6.2 to 9.7)	6.4 (5.3 to 7.8)	8.1 (6.5 to 10)	
Anti-6B,PRE (N=38,39,40)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	
Anti-6B,PIII(M3) (N=44,43,43)	2.3 (1.4 to 3.8)	1.5 (0.9 to 2.4)	1.5 (0.8 to 2.7)	
Anti-9V,PRE (N=37,39,39)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.3)	0.1 (0.1 to 0.1)	
Anti-9V,PIII(M3) (N=43,43,43)	5.8 (4.4 to 7.7)	4.1 (3 to 5.6)	6 (4.5 to 8.1)	
Anti-14,PRE (N=39,38,40)	0.8 (0.6 to 1.2)	1.1 (0.7 to 1.6)	0.7 (0.4 to 1)	
Anti-14,PIII(M3) (N=44,44,43)	3.6 (2.5 to 5.3)	3.3 (2.3 to 4.7)	4.2 (2.8 to 6.2)	
Anti-18C, PRE (N=42,40,42)	0.1 (0.1 to 0.1)	0.2 (0.1 to 0.2)	0.1 (0.1 to 0.1)	
Anti-18C, PIII(M3) (N=43,44,43)	7.2 (5.7 to 9)	5.1 (3.8 to 7)	6.1 (4.2 to 8.8)	
Anti-19F, PRE (N=37,38,40)	0.4 (0.3 to 0.6)	0.5 (0.3 to 0.7)	0.3 (0.2 to 0.5)	
Anti-19F, PIII(M3) (N=44,44,43)	5.8 (4.1 to 8.2)	5.4 (4.2 to 6.9)	5.9 (4.5 to 7.5)	
Anti-23F,PRE (N=41,40,42)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	0.1 (0.1 to 0.1)	
Anti-23F, PIII(M3) (N=44,43,43)	3.2 (2.1 to 4.8)	3 (2 to 4.6)	3.8 (2.5 to 5.7)	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of subjects with serious adverse events (SAEs)

End point title	Number of subjects with serious adverse events (SAEs) <sup>[47]</sup>
-----------------	---

End point description:

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

End point type	Secondary
----------------	-----------

End point timeframe:

From Day 0 up to 12 months post last vaccination

Notes:

[47] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting values for the SB692342 2 dose Group, the SB692342 1 dose Group and the Control Menjugate Group from the baseline period.

End point values	SB692342 2 dose Group	SB692392 2 dose + Tritanrix + Pevnar + Polio Sabin Group	SB692342 1 dose Group	SB692392 1 dose + Tritanrix + Pevnar + Polio Sabin Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	50	49	50	52
Units: Subjects				
Any SAEs	2	1	3	1

End point values	Control Menjugate Group	Control Tritanrix + Pevnar + Polio Sabin Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	50	49		
Units: Subjects				
Any SAEs	3	1		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects with Normal, grade 1 (G1), grade 2 (G2) or grade 4 (G4) Haematological and Biochemical Markers

End point title	Number of Subjects with Normal, grade 1 (G1), grade 2 (G2) or grade 4 (G4) Haematological and Biochemical Markers <sup>[48]</sup>
-----------------	---

End point description:

Levels assessed for Haemoglobin (Haem), White Blood Cells (WBC), Platelets (PLA), Alanine Aminotransferase (ALA) and Creatinine (CREA) were: normal, G1, G2 and G4 . Values that did not fall under normal levels or assessed grades were missing.

End point type	Secondary
----------------	-----------

End point timeframe:

Before vaccination (PRE)

Notes:

[48] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting values for the SB692342 2 dose Group, the SB692342 1 dose Group and the Control Menjugate Group from the baseline period.

End point values	SB692342 2 dose Group	SB692392 2 dose + Tritanrix + Pevnar + Polio Sabin Group	SB692342 1 dose Group	SB692392 1 dose + Tritanrix + Pevnar + Polio Sabin Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	50	49	50	52
Units: Subjects				
Haem, PRE, Normal	49	48	50	51
Haem, PRE, G1	0	1	0	0



Haem, PRE, G2	1	0	0	1
Haem, PRE, G4	0	0	0	0
WBC, PRE, Normal	45	48	49	52
WBC, PRE, G1	0	0	0	0
WBC, PRE, G2	0	0	0	0
WBC, PRE, G4	0	0	0	0
PLA, PRE, Normal	48	49	49	52
PLA, PRE, G1	2	0	0	0
PLA, PRE, G2	0	0	0	0
PLA, PRE, G4	0	0	0	0
ALA, PRE, Normal	42	47	39	51
ALA, PRE, G1	0	1	0	0
ALA, PRE, G2	0	0	0	0
ALA, PRE, G4	0	0	0	0
CREA PRE, Normal	42	48	39	51
CREA PRE, G1	0	0	0	0
CREA PRE, G2	0	0	0	0
CREA PRE, G4	0	0	0	0
Haem, PRE, Missing	0	0	0	0
WBC, PRE, Missing	5	1	1	0
PLA, PRE, Missing	0	0	0	0
ALA, PRE, Missing	8	1	11	1
CREA, PRE, Missing	8	1	11	1

<b>End point values</b>	Control Menjugate Group	Control Tritanrix + Prevnar + Polio Sabin Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	50	49		
Units: Subjects				
Haem, PRE, Normal	48	49		
Haem, PRE, G1	1	0		
Haem, PRE, G2	0	0		
Haem, PRE, G4	0	0		
WBC, PRE, Normal	43	47		
WBC, PRE, G1	0	0		
WBC, PRE, G2	0	0		
WBC, PRE, G4	0	0		
PLA, PRE, Normal	48	49		
PLA, PRE, G1	1	0		
PLA, PRE, G2	0	0		
PLA, PRE, G4	0	0		
ALA, PRE, Normal	40	48		
ALA, PRE, G1	0	1		
ALA, PRE, G2	1	0		
ALA, PRE, G4	0	0		
CREA PRE, Normal	41	49		
CREA PRE, G1	0	0		
CREA PRE, G2	0	0		

CREA, PRE, G4	0	0		
Haem, PRE, Missing	1	0		
WBC, PRE, Missing	7	2		
PLA, PRE, Missing	1	0		
ALA, PRE, Missing	9	0		
CREA, PRE, Missing	9	0		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects with Normal, G1, G2, or G4 Haematological and Biochemical Markers

End point title	Number of Subjects with Normal, G1, G2, or G4 Haematological and Biochemical Markers <sup>[49]</sup>
-----------------	--

End point description:

Levels assessed for Haemoglobin (Haem), White Blood Cells (WBC), Platelets (PLA), Alanine Aminotransferase (ALA) and Creatinine (CREA) were : normal, grade 1 (G1), grade 2 (G2) and grade 4 (G4). Values that did not fall under normal levels or assessed grades were missing.

End point type	Secondary
----------------	-----------

End point timeframe:

Seven days post Dose 1 [PI(D7)]

Notes:

[49] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting values for the SB692342 2 dose Group, the SB692342 1 dose Group and the Control Menjugate Group from the baseline period.

End point values	SB692342 2 dose Group	SB692342 1 dose Group	Control Menjugate Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	50	50	50	
Units: Subjects				
Haem, PI(D7), Normal	49	48	48	
Haem, PI(D7), G1	0	0	0	
Haem, PI(D7), G2	0	0	0	
Haem, PI(D7), G4	0	0	0	
WBC, PI(D7), Normal	46	47	45	
WBC, PI(D7), G1	0	0	0	
WBC, PI(D7), G2	0	0	0	
WBC, PI(D7), G4	0	0	0	
PLA, PI(D7), Normal	49	49	47	
PLA, PI(D7), G1	0	1	1	
PLA, PI(D7), G2	0	0	0	
PLA, PI(D7), G4	0	0	0	
ALA, PI(D7), Normal	48	48	48	
ALA, PI(D7), G1	0	0	0	
ALA, PI(D7), G2	0	0	0	
ALA, PI(D7), G4	0	0	0	

CREA PI(D7), Normal	48	48	49	
CREA PI(D7), G1	0	0	0	
CREA PI(D7), G2	0	0	0	
CREA PI(D7), G4	0	0	0	
Haem, PI(D7), Missing	1	2	0	
WBC, PI(D7), Missing	4	3	5	
PLA, PI(D7), Missing	0	0	1	
ALA, PI(D7), Missing	2	2	2	
CREA, PI(D7), Missing	2	2	1	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects with Normal, G1, G2, or G4 Haematological and Biochemical Markers

End point title	Number of Subjects with Normal, G1, G2, or G4 Haematological and Biochemical Markers <sup>[50]</sup>
-----------------	--

End point description:

Levels assessed for Haemoglobin (Haem), White Blood Cells (WBC), Platelets (PLA), Alanine Aminotransferase (ALA) and Creatinine (CREA) were: normal, grade 1 (G1), grade 2 (G2) and grade 4 (G4). Values that did not fall under normal levels or assessed grades were missing.

End point type	Secondary
----------------	-----------

End point timeframe:

Seven days post Dose 2 [PII(D37)]

Notes:

[50] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting values for the SB692342 2 dose Group and the Control Menjugate Group from the baseline period.

End point values	SB692342 2 dose Group	SB692392 2 dose + Tritanrix + Prevnar + Polio Sabin Group	SB692392 1 dose + Tritanrix + Prevnar + Polio Sabin Group	Control Menjugate Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	50	49	52	50
Units: Subjects				
Haem, PII(D37), Normal	47	45	0	47
Haem, PII(D37), G1	1	0	0	1
Haem, PII(D37), G2	0	0	0	0
Haem, PII(D37), G4	0	0	0	0
WBC, PII(D37), Normal	42	44	0	44
WBC, PII(D37), G1	0	0	0	0
WBC, PII(D37), G2	0	0	0	0
WBC, PII(D37), G4	0	0	0	0
PLA, PII(D37), Normal	47	45	0	48
PLA, PII(D37), G1	1	0	0	0
PLA, PII(D37), G2	0	0	0	0
PLA, PII(D37), G4	0	0	0	0

ALA, PII(D37), Normal	48	46	0	48
ALA, PII(D37), G1	0	0	0	0
ALA, PII(D37), G2	0	0	0	0
ALA, PII(D37), G4	0	0	0	0
CREA PII(D37), Normal	48	46	0	48
CREA PII(D37), G1	0	0	0	0
CREA PII(D37), G2	0	0	0	0
CREA PII(D37), G4	0	0	0	0
Haem, PII(D36), Missing	2	4	52	2
WBC, PII(D36), Missing	8	5	52	6
PLA, PII(D36), Missing	2	4	52	2
ALA, PII(D36), Missing	2	3	52	2
CREA, PII(D36), Missing	2	3	52	2

<b>End point values</b>	Control Tritanrix + Prevnam + Polio Sabin Group			
Subject group type	Reporting group			
Number of subjects analysed	49			
Units: Subjects				
Haem, PII(D37), Normal	47			
Haem, PII(D37), G1	0			
Haem, PII(D37), G2	0			
Haem, PII(D37), G4	0			
WBC, PII(D37), Normal	44			
WBC, PII(D37), G1	0			
WBC, PII(D37), G2	0			
WBC, PII(D37), G4	0			
PLA, PII(D37), Normal	47			
PLA, PII(D37), G1	0			
PLA, PII(D37), G2	0			
PLA, PII(D37), G4	0			
ALA, PII(D37), Normal	47			
ALA, PII(D37), G1	0			
ALA, PII(D37), G2	0			
ALA, PII(D37), G4	0			
CREA PII(D37), Normal	47			
CREA PII(D37), G1	0			
CREA PII(D37), G2	0			
CREA PII(D37), G4	0			
Haem, PII(D36), Missing	2			
WBC, PII(D36), Missing	5			
PLA, PII(D36), Missing	2			
ALA, PII(D36), Missing	2			
CREA, PII(D36), Missing	2			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects with Normal, G1, G2, or G4 Haematological and Biochemical Markers

End point title	Number of Subjects with Normal, G1, G2, or G4 Haematological and Biochemical Markers
-----------------	--

End point description:

Levels assessed for Haemoglobin (Haem), White Blood Cells (WBC), Platelets (PLA), Alanine Aminotransferase (ALA) and Creatinine (CREA) were: normal, grade 1 (G1), grade 2 (G2) and grade 4 (G4). Values that did not fall under normal levels or assessed grades were missing.

End point type	Secondary
End point timeframe:	
Seven days post Dose 3 [PIII(D67)]	

End point values	SB692392 2 dose + Tritanrix + Pevnar + Polio Sabin Group	SB692392 1 dose + Tritanrix + Pevnar + Polio Sabin Group	Control Tritanrix + Pevnar + Polio Sabin Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	49	52	49	
Units: Subjects				
Haem, PIII(D67), Normal	46	51	46	
Haem, PIII(D67), G1	0	0	0	
Haem, PIII(D67), G2	0	0	0	
Haem, PIII(D67), G4	0	0	0	
WBC, PIII(D67), Normal	44	49	46	
WBC, PIII(D67), G1	0	0	0	
WBC, PIII(D67), G2	0	0	0	
WBC, PIII(D67), G4	0	0	0	
PLA, PIII(D67), Normal	46	51	46	
PLA, PIII(D67), G1	0	0	0	
PLA, PIII(D67), G2	0	0	0	
PLA, PIII(D67), G4	0	0	0	
ALA, PIII(D67), Normal	46	51	45	
ALA, PIII(D67), G1	0	1	0	
ALA, PIII(D67), G2	0	0	0	
ALA, PIII(D67), G4	0	0	0	
CREA PIII(D67), Normal	46	52	45	
CREA PIII(D67), G1	0	0	0	
CREA PIII(D67), G2	0	0	0	
CREA PIII(D67), G4	0	0	0	
Haem, PIII(D67), Missing	3	1	3	
WBC, PIII(D67), Missing	5	3	3	
PLA, PIII(D67), Missing	3	1	3	
ALA, PIII(D67), Missing	3	0	4	
CREA, PIII(D67), Missing	3	0	4	

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects with Normal, G1, G2, or G4 Haematological and Biochemical Markers

End point title	Number of Subjects with Normal, G1, G2, or G4 Haematological and Biochemical Markers <sup>[51]</sup>
-----------------	--

End point description:

Levels assessed for Haemoglobin (Haem), White Blood Cells (WBC), Platelets (PLA), Alanine Aminotransferase (ALA) and Creatinine (CREA) were: normal, grade 1 (G1), grade 2 (G2) and grade 4 (G4). Values that did not fall under normal levels or assessed grades were missing.

End point type	Secondary
----------------	-----------

End point timeframe:

One Month post Dose 1 [PI(M1)]

Notes:

[51] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting values for the SB692342 2 dose Group, the SB692342 1 dose Group and the Control Menjugate Group from the baseline period.

End point values	SB692342 2 dose Group	SB692342 1 dose Group	Control Menjugate Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	50	50	50	
Units: Subjects				
Haem, PI(M1), Normal	0	45	0	
Haem, PI(M1), G1	0	2	0	
Haem, PI(M1), G2	0	0	0	
Haem, PI(M1), G4	0	0	0	
WBC, PI(M1), Normal	0	46	0	
WBC, PI(M1), G1	0	0	0	
WBC, PI(M1), G2	0	0	0	
WBC, PI(M1), G4	0	0	0	
PLA, PI(M1), Normal	0	47	0	
PLA, PI(M1), G1	0	0	0	
PLA, PI(M1), G2	0	0	0	
PLA, PI(M1), G4	0	0	0	
ALA, PI(M1), Normal	0	42	0	
ALA, PI(M1), G1	0	0	0	
ALA, PI(M1), G2	0	0	0	
ALA, PI(M1), G4	0	0	0	
CREA PI(M1), Normal	0	42	0	
CREA PI(M1), G1	0	0	0	
CREA PI(M1), G2	0	0	0	

CREA, PI(M1), G4	0	0	0	
Haem, PI(M1), Missing	50	3	50	
WBC, PI(M1), Missing	50	4	50	
PLA, PI(M1), Missing	50	3	50	
ALA, PI(M1), Missing	50	8	50	
CREA, PI(M1), Missing	50	8	50	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects with Normal, G1, G2, or G4 Haematological and Biochemical Markers

End point title	Number of Subjects with Normal, G1, G2, or G4 Haematological and Biochemical Markers <sup>[52]</sup>
-----------------	--

End point description:

Levels assessed for Haemoglobin (Haem), White Blood Cells (WBC), Platelets (PLA), Alanine Aminotransferase (ALA) and Creatinine (CREA) were: normal, grade 1 (G1), grade 2 (G2) and grade 4 (G4). Values that did not fall under normal levels or assessed grades were missing.

End point type	Secondary
----------------	-----------

End point timeframe:

One Month post Dose 2 [PII(M2)]

Notes:

[52] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting values for the SB692342 2 dose Group and the Control Menjugate Group from the baseline period.

End point values	SB692342 2 dose Group	Control Menjugate Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	50	50		
Units: Subjects				
Haem, PII(M2), Normal	47	44		
Haem, PII(M2), G1	0	0		
Haem, PII(M2), G2	0	0		
Haem, PII(M2), G4	0	0		
WBC, PII(M2), Normal	45	41		
WBC, PII(M2), G1	0	0		
WBC, PII(M2), G2	0	0		
WBC, PII(M2), G4	0	0		
PLA, PII(M2), Normal	47	44		
PLA, PII(M2), G1	0	0		
PLA, PII(M2), G2	0	0		
PLA, PII(M2), G4	0	0		
ALA, PII(M2), Normal	42	36		
ALA, PII(M2), G1	0	0		
ALA, PII(M2), G2	0	0		
ALA, PII(M2), G4	0	0		

CREA PII(M2), Normal	42	36		
CREA PII(M2), G1	0	0		
CREA PII(M2), G2	0	0		
CREA PII(M2), G4	0	0		
Haem, PII(M2), Missing	3	6		
WBC, PII(M2), Missing	5	9		
PLA, PII(M2), Missing	3	6		
ALA, PII(M2), Missing	8	14		
CREA, PII(M2), Missing	8	14		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects with Normal, G1, G2, or G4 Haematological and Biochemical Markers

End point title	Number of Subjects with Normal, G1, G2, or G4 Haematological and Biochemical Markers
-----------------	--

End point description:

Levels assessed for Haemoglobin (Haem), White Blood Cells (WBC), Platelets (PLA), Alanine Aminotransferase (ALA) and Creatinine (CREA) were: normal, grade 1 (G1), grade 2 (G2) and grade 4 (G4). Values that did not fall under normal levels or assessed grades were missing.

End point type	Secondary
----------------	-----------

End point timeframe:

One Month post Dose 3 [PIII(M3)]

End point values	SB692392 2 dose + Tritanrix + Pevnar + Polio Sabin Group	SB692392 1 dose + Tritanrix + Pevnar + Polio Sabin Group	Control Tritanrix + Pevnar + Polio Sabin Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	49	52	49	
Units: Subjects				
Haem, PIII(M3), Normal	46	49	44	
Haem, PIII(M3), G1	0	0	0	
Haem, PIII(M3), G2	0	0	0	
Haem, PIII(M3), G4	0	0	0	
WBC, PIII(M3), Normal	45	48	43	
WBC, PIII(M3), G1	0	0	0	
WBC, PIII(M3), G2	0	0	0	
WBC, PIII(M3), G4	0	0	0	
PLA, PIII(M3), Normal	46	48	44	
PLA, PIII(M3), G1	0	0	0	
PLA, PIII(M3), G2	0	0	0	
PLA, PIII(M3), G4	0	0	0	
ALA, PIII(M3), Normal	46	50	44	
ALA, PIII(M3), G1	0	0	0	



ALA, PIII(M3), G2	0	0	0	
ALA, PIII(M3), G4	0	0	0	
CREA PIII(M3), Normal	46	50	44	
CREA PIII(M3), G1	0	0	0	
CREA PIII(M3), G2	0	0	0	
CREA PIII(M3), G4	0	0	0	
Haem, PIII(M3), Missing	3	3	5	
WBC, PIII(M3), Missing	4	4	6	
PLA, PIII(M3), Missing	3	3	5	
ALA, PIII(M3), Missing	3	2	5	
CREA, PIII(M3), Missing	3	2	5	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects with Normal, G1, G2, or G4 Haematological and Biochemical Markers

End point title	Number of Subjects with Normal, G1, G2, or G4 Haematological and Biochemical Markers <sup>[53]</sup>
-----------------	--

End point description:

Levels assessed for Haemoglobin (Haem), White Blood Cells (WBC), Platelets (PLA), Alanine Aminotransferase (ALA) and Creatinine (CREA) were : normal, grade 1 (G1), grade 2 (G2) and grade 4 (G4). Values that did not fall under normal levels or assessed grades were missing.

End point type	Secondary
----------------	-----------

End point timeframe:

Six Months post Dose 1 [PI(M6)]

Notes:

[53] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting values for the SB692342 1 dose Group from the baseline period.

End point values	SB692342 1 dose Group			
Subject group type	Reporting group			
Number of subjects analysed	50			
Units: Subjects				
Haem, PI(M6), Normal	41			
Haem, PI(M6), G1	4			
Haem, PI(M6), G2	1			
Haem, PI(M6), G4	0			
WBC, PI(M6), Normal	45			
WBC, PI(M6), G1	0			
WBC, PI(M6), G2	0			
WBC, PI(M6), G4	0			
PLA, PI(M6), Normal	46			
PLA, PI(M6), G1	0			
PLA, PI(M6), G2	0			
PLA, PI(M6), G4	0			

ALA, PI(M6), Normal	45			
ALA, PI(M6), G1	1			
ALA, PI(M6), G2	0			
ALA, PI(M6), G4	0			
CREA PI(M6), Normal	46			
CREA PI(M6), G1	0			
CREA PI(M6), G2	0			
CREA PI(M6), G4	0			
Haem, PI(M6), Missing	4			
WBC, PI(M6), Missing	5			
PLA, PI(M6), Missing	4			
ALA, PI(M6), Missing	4			
CREA, PI(M6), Missing	4			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects with Normal, G1, G2, or G4 Haematological and Biochemical Markers

End point title	Number of Subjects with Normal, G1, G2, or G4 Haematological and Biochemical Markers <sup>[54]</sup>
-----------------	--

End point description:

Levels assessed for Haemoglobin (Haem), White Blood Cells (WBC), Platelets (PLA), Alanine Aminotransferase (ALA) and Creatinine (CREA) were: normal, grade 1 (G1), grade 2 (G2) and grade 4 (G4). Values that did not fall under normal levels or assessed grades were missing.

End point type	Secondary
----------------	-----------

End point timeframe:

Six Months post Dose 2 [PII(M7)]

Notes:

[54] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting values for the SB692342 2 dose Group and the Control Menjugate Group from the baseline period.

End point values	SB692342 2 dose Group	Control Menjugate Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	50	50		
Units: Subjects				
Haem, PII(M7), Normal	42	41		
Haem, PII(M7), G1	3	3		
Haem, PII(M7),G2	0	0		
Haem, PII(M7),G4	0	0		
WBC, PII(M7), Normal	42	44		
WBC, PII(M7), G1	0	0		
WBC, PII(M7), G2	0	0		
WBC, PII(M7), G4	0	0		
PLA, PII(M7), Normal	45	44		

PLA, PII(M7), G1	0	0		
PLA, PII(M7), G2	0	0		
PLA, PII(M7), G4	0	0		
ALA, PII(M7), Normal	43	43		
ALA, PII(M7), G1	0	0		
ALA, PII(M7), G2	0	0		
ALA, PII(M7), G4	0	0		
CREA PII(M7), Normal	43	43		
CREA PII(M7), G1	0	0		
CREA PII(M7), G2	0	0		
CREA PII(M7), G4	0	0		
Haem, PII(M7), Missing	5	6		
WBC, PII(M7), Missing	8	6		
PLA, PII(M7), Missing	5	6		
ALA, PII(M7), Missing	7	7		
CREA, PII(M7), Missing	7	7		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects with Normal, G1, G2, or G4 Haematological and Biochemical Markers

End point title	Number of Subjects with Normal, G1, G2, or G4 Haematological and Biochemical Markers
-----------------	--

End point description:

Levels assessed for Haemoglobin (Haem), White Blood Cells (WBC), Platelets (PLA), Alanine Aminotransferase (ALA) and Creatinine (CREA) were: normal, grade 1 (G1), grade 2 (G2) and grade 4 (G4). Values that did not fall under normal levels or assessed grades were missing.

End point type	Secondary
----------------	-----------

End point timeframe:

Six Months post Dose 3 [PIII(M8)]

End point values	SB692392 2 dose + Tritanrix + Pevnar + Polio Sabin Group	SB692392 1 dose + Tritanrix + Pevnar + Polio Sabin Group	Control Tritanrix + Pevnar + Polio Sabin Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	49	52	49	
Units: Subjects				
Haem, PIII(M8), Normal	43	47	44	
Haem, PIII(M8), G1	1	4	2	
Haem, PIII(M8), G2	0	0	0	
Haem, PIII(M8), G4	0	0	0	
WBC, PIII(M8), Normal	41	47	41	
WBC, PIII(M8), G1	0	0	0	
WBC, PIII(M8), G2	0	0	0	

WBC, PIII(M8), G4	0	0	0	
PLA, PIII(M8), Normal	44	50	46	
PLA, PIII(M8), G1	0	1	0	
PLA, PIII(M8), G2	0	0	0	
PLA, PIII(M8), G4	0	0	0	
ALA, PIII(M8), Normal	43	50	46	
ALA, PIII(M8), G1	1	0	0	
ALA, PIII(M8), G2	0	0	0	
ALA, PIII(M8), G4	0	0	0	
CREA PIII(M8), Normal	43	51	46	
CREA PIII(M8), G1	0	0	0	
CREA PIII(M8), G2	0	0	0	
CREA PIII(M8), G4	0	0	0	
Haem, PIII(M8), Missing	5	1	3	
WBC, PIII(M8), Missing	8	5	8	
PLA, PIII(M8), Missing	5	1	3	
ALA, PIII(M8), Missing	5	1	3	
CREA, PIII(M8), Missing	6	1	3	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects with Normal, G1, G2, or G4 Haematological and Biochemical Markers

End point title	Number of Subjects with Normal, G1, G2, or G4 Haematological and Biochemical Markers <sup>[55]</sup>
-----------------	--

End point description:

Levels assessed for Haemoglobin (Haem), White Blood Cells (WBC), Platelets (PLA), Alanine Aminotransferase (ALA) and Creatinine (CREA) were: normal, grade 1 (G1), grade 2 (G2) and grade 4 (G4). Values that did not fall under normal levels or assessed grades were missing.

End point type	Secondary
----------------	-----------

End point timeframe:

Six Months post Dose 3 [PIII(M13)]

Notes:

[55] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting values for the SB692342 2 dose Group and the Control Menjugate Group from the baseline period.

End point values	SB692342 2 dose Group	Control Menjugate Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	50	50		
Units: Subjects				
Haem, PIII(M13), Normal	0	43		
Haem, PIII(M13), G1	0	1		
Haem, PIII(M13), G2	0	0		
Haem, PIII(M13), G4	0	0		

WBC, PIII(M13), Normal	0	42		
WBC, PIII(M13), G1	0	0		
WBC, PIII(M13), G2	0	0		
WBC, PIII(M13), G4	0	0		
PLA, PIII(M13), Normal	0	44		
PLA, PIII(M13), G1	0	0		
PLA, PIII(M13), G2	0	0		
PLA, PIII(M13), G4	0	0		
ALA, PIII(M13), Normal	0	44		
ALA, PIII(M13), G1	0	0		
ALA, PIII(M13), G2	0	0		
ALA, PIII(M13), G4	0	0		
CREA PIII(M13), Normal	0	44		
CREA PIII(M13), G1	0	0		
CREA PIII(M13), G2	0	0		
CREA PIII(M13), G4	0	0		
Haem, PIII(M13), Missing	50	6		
WBC, PIII(M13), Missing	50	8		
PLA, PIII(M13), Missing	50	6		
ALA, PIII(M13), Missing	50	6		
CREA, PIII(M13), Missing	50	6		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects with Normal, G1, G2, or G4 Haematological and Biochemical Markers

End point title	Number of Subjects with Normal, G1, G2, or G4 Haematological and Biochemical Markers <sup>[56]</sup>
-----------------	--

End point description:

Levels assessed for Haemoglobin (Haem), White Blood Cells (WBC), Platelets (PLA), Alanine Aminotransferase (ALA) and Creatinine (CREA) were: normal, grade 1 (G1), grade 2 (G2) and grade 4 (G4). Values that did not fall under normal levels or assessed grades were missing.

End point type	Secondary
----------------	-----------

End point timeframe:

Twelve Months post Dose 1 [PI(M12)]

Notes:

[56] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting values for the SB692342 1 dose Group from the baseline period.

<b>End point values</b>	SB692342 1 dose Group			
Subject group type	Reporting group			
Number of subjects analysed	50			
Units: Subjects				
Haem, PI(M12), Normal	47			
Haem, PI(M12), G1	2			

Haem, PI(M12), G2	0			
Haem, PI(M12), G4	0			
WBC, PI(M12), Normal	48			
WBC, PI(M12), G1	0			
WBC, PI(M12), G2	0			
WBC, PI(M12), G4	0			
PLA, PI(M12), Normal	48			
PLA, PI(M12), G1	1			
PLA, PI(M12), G2	0			
PLA, PI(M12), G4	0			
ALA, PI(M12), Normal	46			
ALA, PI(M12), G1	2			
ALA, PI(M12), G2	1			
ALA, PI(M12), G4	0			
CREA PI(M12), Normal	49			
CREA PI(M12), G1	0			
CREA PI(M12), G2	0			
CREA PI(M12), G4	0			
Haem, PI(M12), Missing	1			
WBC, PI(M12), Missing	2			
PLA, PI(M12), Missing	1			
ALA, PI(M12), Missing	1			
CREA, PI(M12), Missing	1			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects with Normal, G1, G2, or G4 Haematological and Biochemical Markers

End point title	Number of Subjects with Normal, G1, G2, or G4 Haematological and Biochemical Markers <sup>[57]</sup>
-----------------	--

End point description:

Levels assessed for Haemoglobin (Haem), White Blood Cells (WBC), Platelets (PLA), Alanine Aminotransferase (ALA) and Creatinine (CREA) were: normal, grade 1 (G1), grade 2 (G2) and grade 4 (G4). Values that did not fall under normal levels or assessed grades were missing.

End point type	Secondary
----------------	-----------

End point timeframe:

Twelve Months post Dose 2 [PII(M13)]

Notes:

[57] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only reporting values for the SB692342 2 dose Group and the Control Menjugate Group from the baseline period.

End point values	SB692342 2 dose Group	Control Menjugate Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	50	50		
Units: Subjects				
Haem, PII(M13), Normal	41	0		
Haem, PII(M13), G1	4	0		
Haem, PII(M13), G2	1	0		
Haem, PII(M13), G4	0	0		
WBC, PII(M13), Normal	43	0		
WBC, PII(M13), G1	0	0		
WBC, PII(M13), G2	0	0		
WBC, PII(M13), G4	0	0		
PLA, PII(M13), Normal	46	0		
PLA, PII(M13), G1	0	0		
PLA, PII(M13), G2	0	0		
PLA, PII(M13), G4	0	0		
ALA, PII(M13), Normal	45	0		
ALA, PII(M13), G1	1	0		
ALA, PII(M13), G2	0	0		
ALA, PII(M13), G4	0	0		
CREA PII(M13), Normal	46	0		
CREA PII(M13), G1	0	0		
CREA PII(M13), G2	0	0		
CREA PII(M13), G4	0	0		
Haem, PII(M13), Missing	4	50		
WBC, PII(M13), Missing	7	50		
PLA, PII(M13), Missing	4	50		
ALA, PII(M13), Missing	4	50		
CREA, PII(M13), Missing	4	50		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects with Normal, G1, G2, or G4 Haematological and Biochemical Markers

End point title	Number of Subjects with Normal, G1, G2, or G4 Haematological and Biochemical Markers
-----------------	--

End point description:

Levels assessed for Haemoglobin (Haem), White Blood Cells (WBC), Platelets (PLA), Alanine Aminotransferase (ALA) and Creatinine (CREA) were: normal, grade 1 (G1), grade 2 (G2) and grade 4 (G4). Values that did not fall under normal levels or assessed grades were missing.

End point type	Secondary
----------------	-----------

End point timeframe:

Twelve Months post Dose 3 [PIII(M14)]

<b>End point values</b>	SB692392 2 dose + Tritanrix + Prevnam + Polio Sabin Group	SB692392 1 dose + Tritanrix + Prevnam + Polio Sabin Group	Control Tritanrix + Prevnam + Polio Sabin Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	49	52	49	
Units: Subjects				
Haem, PIII(M14), Normal	38	46	37	
Haem, PIII(M14), G1	6	5	8	
Haem, PIII(M14), G2	0	0	0	
Haem, PIII(M14), G4	0	0	0	
WBC, PIII(M14), Normal	42	48	42	
WBC, PIII(M14), G1	0	0	0	
WBC, PIII(M14), G2	0	0	0	
WBC, PIII(M14), G4	0	0	0	
PLA, PIII(M14), Normal	44	51	44	
PLA, PIII(M14), G1	0	0	0	
PLA, PIII(M14), G2	0	0	0	
PLA, PIII(M14), G4	0	0	0	
ALA, PIII(M14), Normal	43	51	43	
ALA, PIII(M14), G1	1	0	1	
ALA, PIII(M14), G2	0	0	0	
ALA, PIII(M14), G4	0	0	0	
CREA PIII(M14), Normal	44	51	44	
CREA PIII(M14), G1	0	0	0	
CREA PIII(M14), G2	0	0	0	
CREA PIII(M14), G4	0	0	0	
Haem, PIII(M14), Missing	5	1	4	
WBC, PIII(M14), Missing	7	4	7	
PLA, PIII(M14), Missing	5	1	4	
ALA, PIII(M14), Missing	5	1	5	
CREA, PIII(M14), Missing	5	1	5	

## Statistical analyses

No statistical analyses for this end point



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Solicited symptoms: during the 7-day post-vaccination period; Unsolicited AEs: during the 30-day post-vaccination period; SAEs: from study start (Day 0) up to one month post-vaccination and from Day 0 up to 12 months post last vaccination.

Adverse event reporting additional description:

Other Adverse Events were collected from all subjects with at least one administered dose with safety follow-up and who completed their symptom sheet.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	14.1
--------------------	------

### Reporting groups

Reporting group title	SB692342 2 dose Group
-----------------------	-----------------------

Reporting group description:

Subjects received two doses of SB692342 vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, 1 month apart, on a 0, 1 month schedule after having completed their primary EPI regimen.

Reporting group title	SB692392 1 dose Group
-----------------------	-----------------------

Reporting group description:

Subjects received one dose of SB692342 vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, at Month 0, after having completed their primary EPI regimen.

Reporting group title	Control Menjugate Group
-----------------------	-------------------------

Reporting group description:

Subjects received three doses of the control Menjugate vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, on a 0, 1, 7 months schedule. The first two doses were administered 1 month apart during the primary vaccination phase and the third dose was administered 6 months after the last primary vaccination dose.

Reporting group title	SB692392 2dose + Tritanrix + Pevnar + Polio Sabin Group
-----------------------	---

Reporting group description:

Subjects received two doses of SB692342 vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, 1 month apart, concomitantly with the last two doses of the primary EPI regimen containing Tritanrix HepB+Hiberix vaccine, administered intramuscularly in the anterolateral region of the left thigh, Polio Sabin vaccine, administered orally, and Pevnar vaccine, administered intramuscularly in the right arm, on a 0, 1, 2 months schedule. All subjects received a booster dose of the Tritanrix HepB+Hiberix, Polio Sabin and Pevnar vaccines approximately 1 year after their last dose.

Reporting group title	SB692392 1 dose + Tritanrix + Pevnar + Polio Sabin Group
-----------------------	--

Reporting group description:

Subjects received one dose of SB692342 vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, concomitantly with the last dose of the primary EPI regimen containing Tritanrix HepB+Hiberix vaccine, administered intramuscularly in the anterolateral region of the left thigh, Polio Sabin™ vaccine, administered orally, and Pevnar vaccine, administered intramuscularly in the right arm, on a 0, 1, 2 months schedule. All subjects received a booster dose of the Tritanrix HepB+Hiberix, Polio Sabin and Pevnar vaccines approximately 1 year after their last dose.

Reporting group title	Control Tritanrix + Pevnar + Polio Sabin Group
-----------------------	--

Reporting group description:

Subjects received three doses of the primary EPI regimen containing Tritanrix HepB+Hiberix vaccine, administered in the anterolateral region of the left thigh, Polio Sabin vaccine, administered orally, and Pevnar vaccine administered intramuscularly in the right arm, on a 0, 1, 2 months schedule. All subjects received a booster dose of the Tritanrix HepB+Hiberix, Polio Sabin and Pevnar vaccines approximately 1 year after their last dose.

<b>Serious adverse events</b>	SB692342 2 dose Group	SB692392 1 dose Group	Control Menjugate Group
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 50 (4.00%)	3 / 50 (6.00%)	3 / 50 (6.00%)
number of deaths (all causes)	0	0	1
number of deaths resulting from adverse events			
Injury, poisoning and procedural complications			
Thermal burn			
subjects affected / exposed	0 / 50 (0.00%)	1 / 50 (2.00%)	0 / 50 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Febrile convulsion			
subjects affected / exposed	0 / 50 (0.00%)	0 / 50 (0.00%)	0 / 50 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	0 / 50 (0.00%)	0 / 50 (0.00%)	1 / 50 (2.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Rash			
subjects affected / exposed	0 / 50 (0.00%)	0 / 50 (0.00%)	1 / 50 (2.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Sepsis			
subjects affected / exposed	0 / 50 (0.00%)	0 / 50 (0.00%)	1 / 50 (2.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Bronchopneumonia			

subjects affected / exposed	2 / 50 (4.00%)	1 / 50 (2.00%)	1 / 50 (2.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	1 / 50 (2.00%)	1 / 50 (2.00%)	0 / 50 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral malaria			
subjects affected / exposed	0 / 50 (0.00%)	0 / 50 (0.00%)	1 / 50 (2.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malaria			
subjects affected / exposed	1 / 50 (2.00%)	0 / 50 (0.00%)	0 / 50 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	SB692392 2dose + Tritanrix + Prevnar + Polio Sabin Group	SB692392 1 dose + Tritanrix + Prevnar + Polio Sabin Group	Control Tritanrix + Prevnar + Polio Sabin Group
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 49 (2.04%)	1 / 52 (1.92%)	1 / 49 (2.04%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Injury, poisoning and procedural complications			
Thermal burn			
subjects affected / exposed	0 / 49 (0.00%)	0 / 52 (0.00%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Febrile convulsion			
subjects affected / exposed	0 / 49 (0.00%)	1 / 52 (1.92%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Pyrexia			

subjects affected / exposed	0 / 49 (0.00%)	0 / 52 (0.00%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Rash			
subjects affected / exposed	0 / 49 (0.00%)	0 / 52 (0.00%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Sepsis			
subjects affected / exposed	0 / 49 (0.00%)	0 / 52 (0.00%)	1 / 49 (2.04%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchopneumonia			
subjects affected / exposed	0 / 49 (0.00%)	0 / 52 (0.00%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	1 / 49 (2.04%)	0 / 52 (0.00%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral malaria			
subjects affected / exposed	0 / 49 (0.00%)	0 / 52 (0.00%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malaria			
subjects affected / exposed	0 / 49 (0.00%)	0 / 52 (0.00%)	0 / 49 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	SB692342 2 dose Group	SB692392 1 dose Group	Control Menjugate Group
Total subjects affected by non-serious adverse events			
subjects affected / exposed	33 / 50 (66.00%)	22 / 50 (44.00%)	31 / 50 (62.00%)
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed <sup>[1]</sup>	3 / 50 (6.00%)	1 / 50 (2.00%)	4 / 50 (8.00%)
occurrences (all)	3	1	4
Pain			
subjects affected / exposed <sup>[2]</sup>	6 / 50 (12.00%)	2 / 50 (4.00%)	6 / 50 (12.00%)
occurrences (all)	6	2	6
Swelling			
subjects affected / exposed <sup>[3]</sup>	0 / 50 (0.00%)	0 / 50 (0.00%)	0 / 50 (0.00%)
occurrences (all)	0	0	0
Drowsiness			
subjects affected / exposed <sup>[4]</sup>	2 / 50 (4.00%)	0 / 50 (0.00%)	1 / 50 (2.00%)
occurrences (all)	2	0	1
Irritability			
subjects affected / exposed <sup>[5]</sup>	3 / 50 (6.00%)	0 / 50 (0.00%)	2 / 50 (4.00%)
occurrences (all)	3	0	2
Loss of appetite			
subjects affected / exposed <sup>[6]</sup>	3 / 50 (6.00%)	0 / 50 (0.00%)	1 / 50 (2.00%)
occurrences (all)	3	0	1
Temperature(Axillary)			
subjects affected / exposed <sup>[7]</sup>	19 / 50 (38.00%)	5 / 50 (10.00%)	13 / 50 (26.00%)
occurrences (all)	19	5	13
Eye disorders			
Conjunctivitis			
subjects affected / exposed <sup>[8]</sup>	0 / 50 (0.00%)	0 / 50 (0.00%)	1 / 50 (2.00%)
occurrences (all)	0	0	1
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed <sup>[9]</sup>	8 / 50 (16.00%)	5 / 50 (10.00%)	2 / 50 (4.00%)
occurrences (all)	8	5	2
Infections and infestations			
Respiratory tract infection			

subjects affected / exposed <sup>[10]</sup>	21 / 50 (42.00%)	14 / 50 (28.00%)	19 / 50 (38.00%)
occurrences (all)	21	14	19

<b>Non-serious adverse events</b>	SB692392 2dose + Tritanrix + Prevnar + Polio Sabin Group	SB692392 1 dose + Tritanrix + Prevnar + Polio Sabin Group	Control Tritanrix + Prevnar + Polio Sabin Group
Total subjects affected by non-serious adverse events			
subjects affected / exposed	34 / 49 (69.39%)	22 / 52 (42.31%)	26 / 49 (53.06%)
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed <sup>[1]</sup>	0 / 47 (0.00%)	2 / 52 (3.85%)	0 / 48 (0.00%)
occurrences (all)	0	2	0
Pain			
subjects affected / exposed <sup>[2]</sup>	10 / 47 (21.28%)	13 / 52 (25.00%)	13 / 48 (27.08%)
occurrences (all)	10	13	13
Swelling			
subjects affected / exposed <sup>[3]</sup>	6 / 47 (12.77%)	8 / 52 (15.38%)	8 / 48 (16.67%)
occurrences (all)	6	8	8
Drowsiness			
subjects affected / exposed <sup>[4]</sup>	3 / 47 (6.38%)	3 / 52 (5.77%)	0 / 48 (0.00%)
occurrences (all)	3	3	0
Irritability			
subjects affected / exposed <sup>[5]</sup>	8 / 47 (17.02%)	5 / 52 (9.62%)	4 / 48 (8.33%)
occurrences (all)	8	5	4
Loss of appetite			
subjects affected / exposed <sup>[6]</sup>	3 / 47 (6.38%)	2 / 52 (3.85%)	0 / 48 (0.00%)
occurrences (all)	3	2	0
Temperature(Axillary)			
subjects affected / exposed <sup>[7]</sup>	18 / 47 (38.30%)	9 / 52 (17.31%)	12 / 48 (25.00%)
occurrences (all)	18	9	12
Eye disorders			
Conjunctivitis			
subjects affected / exposed <sup>[8]</sup>	0 / 47 (0.00%)	0 / 52 (0.00%)	3 / 48 (6.25%)
occurrences (all)	0	0	3
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed <sup>[9]</sup>	5 / 47 (10.64%)	1 / 52 (1.92%)	3 / 48 (6.25%)
occurrences (all)	5	1	3

Infections and infestations			
Respiratory tract infection			
subjects affected / exposed <sup>[10]</sup>	15 / 47 (31.91%)	9 / 52 (17.31%)	14 / 48 (29.17%)
occurrences (all)	15	9	14

Notes:

[1] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Assessment for this event for this phase was performed solely on subjects with their symptom sheets completed.

[2] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Assessment for this event for this phase was performed solely on subjects with their symptom sheets completed.

[3] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Assessment for this event for this phase was performed solely on subjects with their symptom sheets completed.

[4] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Assessment for this event for this phase was performed solely on subjects with their symptom sheets completed.

[5] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Assessment for this event for this phase was performed solely on subjects with their symptom sheets completed.

[6] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Assessment for this event for this phase was performed solely on subjects with their symptom sheets completed.

[7] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Assessment for this event for this phase was performed solely on subjects with their symptom sheets completed.

[8] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Assessment for this event for this phase was performed solely on subjects with their symptom sheets completed.

[9] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Assessment for this event for this phase was performed solely on subjects with their symptom sheets completed.

[10] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Assessment for this event for this phase was performed solely on subjects with their symptom sheets completed.

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
19 November 2010	The purpose of this amendment is to apply a standard and robust methodology for the collection, documentation and safety monitoring of serious and nonserious potential immune mediated disorders (pIMDs) as adverse events of special interest occurring in subjects participating in clinical trials evaluating GSK adjuvant containing vaccines. Guidance for what is considered as to be potentially immune mediated and time period of pIMD reporting are included in this amendment.
28 July 2011	The pneumococcal conjugate vaccine (PCV) being administered as part of the EPI vaccination in this study is Prevnar (7-valent PCV). The manufacturing company (Wyeth) has stopped production and marketing of 7-valent PCV which was initially used in the study. It currently produces and markets the 13-valent PCV (Prevnar 13). The SPC shows that the 13-valent PCV can be given after the 7-valent PCV with no safety issues. Hence for the booster dose, subjects in this study will be given the 13- valent PCV. This change in formulation of the administered vaccine is not expected to have an impact on the analysis of any study endpoints. The protocol has been amended to include a description of the 13-valent PCV.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported